US 20200248174A1

(19) **United States**
(12) **Patent Application Publication**
Nishida et al.
(10) **Pub. No.: US 2020/0248174 A1**
(43) **Pub. Date: Aug. 6, 2020**

(54) **GENOMIC SEQUENCE MODIFICATION METHOD FOR SPECIFICALLY CONVERTING NUCLEIC ACID BASES OF TARGETED DNA SEQUENCE, AND MOLECULAR COMPLEX FOR USE IN SAME**

(71) Applicant: **NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY**, Kobe-shi (JP)

(72) Inventors: **Keiji Nishida**, Kobe-shi, Hyogo (JP); **Akihiko Kondo**, Kobe-shi, Hyogo (JP); **Satomi Kojima**, Kobe-shi, Hyogo (JP)

(21) Appl. No.: **16/838,960**

(22) Filed: **Apr. 2, 2020**

Related U.S. Application Data

(63) Continuation of application No. 15/124,021, filed on Nov. 9, 2016, now Pat. No. 10,655,123, filed as application No. PCT/JP2015/056436 on Mar. 4, 2015.

(30) **Foreign Application Priority Data**

Mar. 5, 2014 (JP) 2014-043348
Sep. 30, 2014 (JP) 2014-201859

Publication Classification

(51) **Int. Cl.**

C12N 15/10	(2006.01)
C12N 9/22	(2006.01)
C12N 9/78	(2006.01)
C12N 15/11	(2006.01)

(52) **U.S. Cl.**

CPC ***C12N 15/1024*** (2013.01); ***C12N 9/22*** (2013.01); ***C12N 15/102*** (2013.01); ***C12N 9/78*** (2013.01); *C12N 2310/3513* (2013.01); ***C12Y 305/04005*** (2013.01); *C07K 2319/00* (2013.01); *C07K 2319/81* (2013.01); ***C12N 15/11*** (2013.01)

(57) **ABSTRACT**

The invention provides a method of modifying a targeted site of a double stranded DNA, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and a nucleic acid base converting enzyme are linked, with the double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one strand of the double stranded DNA in the targeted site.

Specification includes a Sequence Listing.

Fig. 1



Fig. 2



Fig. 3



Fig. 4



Fig. 5



Fig. 6

Change of mutation introduction pattern

target sequence





Fig. 7



Fig. 8



Clone No	Mutation	Amino acid	Canavanine resistance
[illegible]	CC795TT	P266S	
[illegible]	CC795AAT	Frame	CanR
[illegible]	CC795TT	P266S	
[illegible]	CC796TT	P266L	CanR
[illegible]	CC795AT	P266S	
[illegible]	CC795AAT	Frame	CanR
[illegible]	CC796TT	P266L	CanR
[illegible]	CC795AT	P266S	
[illegible]	CC796TT	P266L	CanR
[illegible]	CC795TT	P266S	

Fig. 9

Red/ White	CanR	Ade1 (3)	Can1 (767)
		TAACG ATA ATG TCA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CGT TAT TGG AGA AAC C
		M S I T K T E L D G I	G V T G P V G F R Y W R N
R	R	TAACG ATA ATG TCA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CGT TAT TGG AGA AAC C
R	R	TAACG ATA ATG TCA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CGT TAT TGG AGA AAC C
R	R	TAACG ATA ATG TCA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CGT TAT TGG AGA AAC C
R	R	TAACG ATA ATG TCA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CGT TAT TGG AGA AAC C
R	S	TAACG ATA ATG TCA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CAT TAT TGG AGA AAC C
W	R	TAACG ATA ATG TTA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GAA TTC CGT TAT TGG AGA AAC C
W	R	TAACG ATA ATG TTA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CGT TAT TGG AGA AAC C
W	S	TAACG ATA ATG TTA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CTT TAT TGG AGA AAC C
W	S	TAACG ATA ATG TTA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CAT TAT TGG AGA AAC C
W	R	TAACG ATA ATG TTA ATT ACG AAG ACT GAA CTG GAC GGT AT	GGG GTT ACC GGC CCA GTT GGA TTC CGT TAT TGG AGA AAC C

SEQ ID NO for each sequence	
SEQ ID NO: 50	SEQ ID NO: 54
SEQ ID NO: 51	SEQ ID NO: 55
SEQ ID NO: 52	SEQ ID NO: 56
SEQ ID NO: 52	SEQ ID NO: 56
SEQ ID NO: 52	SEQ ID NO: 56
SEQ ID NO: 52	SEQ ID NO: 56
SEQ ID NO: 52	SEQ ID NO: 57
SEQ ID NO: 53	SEQ ID NO: 58
SEQ ID NO: 53	SEQ ID NO: 56
SEQ ID NO: 53	SEQ ID NO: 59
SEQ ID NO: 53	SEQ ID NO: 57
SEQ ID NO: 53	SEQ ID NO: 56

Fig. 10A



Fig. 10B



Fig. 11A



Fig. 11B

galK	TCAATGGGCTAACTACGTTC-3′	(SEQ ID NO:61)
1	TCAATGGGCTAACTACGTTC	(SEQ ID NO:61)
2	TTAATGGGCTAACTACGTTC	(SEQ ID NO:62)
3	TTAATGGGCTAACTACGTTC	(SEQ ID NO:62)

Fig. 11C

rpoB		GCTGTCTCAGTTTATGGACC-3′	(SEQ ID NO:63)
		[CGACAGAGTCAAATACCTGG-5′]	(SEQ ID NO:64)
none	1	GCTGTCTCAGTTTATGGACC	(SEQ ID NO:63)
	2	GCTGTCTCAGTTTATGGACC	(SEQ ID NO:63)
Rif25	1	GCTGTCTCAGTTTATGAACC	(SEQ ID NO:66)
	2	GCTGTCTCAGTTTATGAACC	(SEQ ID NO:66)
Rif50	1	GCTGTCTCAGTTTATAAACC	(SEQ ID NO:67)
	2	GCTGTCTCAGTTTATGAACC	(SEQ ID NO:66)
		[CGACAGAGTCAAATACTTGG-5′]	(SEQ ID NO:68)



Fig. 12A



Fig. 12B

TCGCTTGAACATCCAGCGAAACAGGCCCCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:69)

target 24bp

TCGCTTGAACATCCAGCGAAACAGG-cCCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:70)
TCGCTTGAACATCCAGCGAAACAGG-CcCCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:71)
TCGCTTGAACATCCAGCGAAACAGGcCCCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:72)
TCGCTTGAACATCCAGCGAAACAGGcCcCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:73)
TCGCTTGAACATCCAGCGAAACAGGcCccCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:74)

target 22bp

TCGCTTGAACATCCAGCGAAACAGG-cccCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:75)
TCGCTTGAACATCCAGCGAAACAGGccccCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:76)
TCGCTTGAACATCCAGCGAAACAGGccCcCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:77)
TCGCTTGAACATCCAGCGAAACAGGcC-cCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:78)
TCGCTTGAACATCCAGCGAAACAGGCC--CCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:79)

target 20bp

TCGCTTGAACATCCAGCGAAACAGGCC--CCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:80)
TCGCTTGAACATCCAGCGAAACAGGCC--CCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:81)
TCGCTTGAACATCCAGCGAAACAGGCC--CCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:82)
TCGCTTGAACATCCAGCGAAACAGGCCccCCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:83)

target 18bp

TCGCTTGAACATCCAGCGAAACAGGCC--CCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:84)
TCGCTTGAACATCCAGCGAAACAGGCCC--CCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:85)
TCGCTTGAACATCCAGCGAAACAGGCCCC-CCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:86)
TCGCTTGAACATCCAGCGAAACAGGCCCC-CCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:87)
TCGCTTGAACATCCAGCGAAACAGGCCCC--CCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:88)
TCGCTTGAACATCCAGCGAAACAGGCCCCcCCCATCGAGCAGAAAACGGTGGTGGATGGC (SEQ ID NO:89)

Fig. 13



Fig. 14

mutation introduction method (temperature sensitive plasmid)



Fig. 15





Fig. 16

galK (target 8, target 12)



galK 8 ACTCACACCATTCAGGCGCC -3' (SEQ ID NO:92)

colony1 ACTTACACCATTCAGGCGCC (SEQ ID NO:93)
colony2 ACTTACACCATTCAGGCGCC (c→t) (SEQ ID NO:93)

galK 12 TCAATGGGCTAACTACGTTCG -3' (SEQ ID NO:94)

colony1 TTAATGGGCTAACTACGTTCG (SEQ ID NO:95)
colony2 TTAATGGGCTAACTACGTTCG (c→t) (SEQ ID NO:95)

GENOMIC SEQUENCE MODIFICATION METHOD FOR SPECIFICALLY CONVERTING NUCLEIC ACID BASES OF TARGETED DNA SEQUENCE, AND MOLECULAR COMPLEX FOR USE IN SAME

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This patent application is a continuation of U.S. patent application Ser. No. 15/124,021, filed Nov. 9, 2016; which is the U.S. national phase of International Patent Application No. PCT/JP2015/056436, filed Mar. 4, 2015; which claims the benefit of Japanese Patent Application No. 2014-043348, filed on Mar. 5, 2014, and Japanese Patent Application No. 2014-201859, filed on Sep. 30, 2014, which are incorporated by reference in their entireties herein.

INCORPORATION-BY-REFERENCE OF MATERIAL ELECTRONICALLY SUBMITTED

[0002] Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: 96.9 KB ASCII (Text) file named "150161_401C1_SEQ_LISTING.txt" created Mar. 30, 2020.

TECHNICAL FIELD

[0003] The present invention relates to a modification method of a genome sequence, which enables modification of a nucleic acid base in a particular region of a genome, without cleaving double-stranded DNA (with no cleavage or single strand cleavage), and without inserting a foreign DNA fragment, and a complex of a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme used therefor.

BACKGROUND ART

[0004] In recent years, genome editing is attracting attention as a technique for modifying the target gene and genome region of interest in various species. Conventionally, as a method of genome editing, a method utilizing an artificial nuclease comprising a combination of a molecule having a sequence-independent DNA cleavage ability and a molecule having a sequence recognition ability has been proposed (non-patent document 1).

[0005] For example, a method of performing recombination at a target gene locus in DNA in a plant cell or insect cell as a host, by using a zinc finger nuclease (ZFN) wherein a zinc finger DNA binding domain and a non-specific DNA cleavage domain are linked (patent document 1); a method of cleaving or modifying a target gene in a particular nucleotide sequence or a site adjacent thereto by using TALEN wherein a transcription activator-like (TAL) effector, which is a DNA binding module that the plant pathogenic bacteria Xanthomonas has, and a DNA endonuclease are linked (patent document 2); a method utilizing CRISPR-Cas9 system wherein DNA sequence CRISPR (Clustered Regularly interspaced short palindromic repeats), that functions in an acquired immune system possessed by eubacterium and archaebacterium, and nuclease Cas (CRISPR-associated) protein family having an important function along with CRISPR are combined (patent document 3) and the like have been reported. Furthermore, a method of cleaving a target gene in the vicinity of a particular sequence, by using artificial nuclease wherein a PPR protein configured to recognize a particular nucleotide sequence by a series of PPR motifs each consisting of 35 amino acids and recognizing one nucleic acid base, and nuclease are linked (patent document 4) has also been reported.

DOCUMENT LIST

Patent Documents

[0006] patent document 1: JP-B-4968498

[0007] patent document 2: National Publication of International Patent Application No. 2013-513389

[0008] patent document 3: National Publication of International Patent Application No. 2010-519929

[0009] patent document 4: JP-A-2013-128413

[0010] non-patent document

[0011] non-patent document 1: Kelvin M Esvelt, Harris H Wang (2013) Genome-scale engineering for systems and synthetic biology, Molecular Systems Biology 9: 641

SUMMARY OF THE INVENTION

Problems to be Solved by the Invention

[0012] The genome editing techniques heretofore been proposed basically presuppose double-stranded DNA breaks (DSB). However, since they involve unexpected genome modifications, side effects such as strong cytotoxicity, chromosomal rearrangement and the like occur, and they have common problems of impaired reliability in gene therapy, extremely small number of surviving cells by nucleotide modification, and difficulty in genetic modification itself in primate ovum and unicellular microorganisms.

[0013] Therefore, an object of the present invention is to provide a novel method of genome editing for modifying a nucleic acid base of a particular sequence of a gene without DSB or insertion of foreign DNA fragment, i.e., by non-cleavage of a double stranded DNA or single strand cleavage, and a complex of a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme therefor.

Means of Solving the Problems

[0014] The present inventors have conducted intensive studies in an attempt to solve the above-mentioned problems and taken note of adopting base conversion by a conversion reaction of DNA base, without accompanying DSB. The base conversion reaction by a deamination reaction of DNA base is already known; however, targeting any site by recognizing a particular sequence of DNA, and specifically modifying the targeted DNA by base conversion of DNA bases has not been realized yet.

[0015] Therefore, deaminase, that catalyzes a deamination reaction, was used as an enzyme for such conversion of nucleic acid bases, and linked to a molecule having a DNA sequence recognition ability, thereby a genome sequence was modified by nucleic acid base conversion in a region containing a particular DNA sequence.

[0016] Specifically, CRISPR-Cas system (CRISPR-mutant Cas) was used. That is, a DNA encoding an RNA molecule, wherein genome specific CRISPR-RNA:crRNA (gRNA) containing a sequence complementary to a target sequence of a gene to be modified is linked to an RNA for recruiting Cas protein (trans-activating crRNA: tracrRNA)

was produced. On the other hand, a DNA wherein a DNA encoding a mutant Cas protein (dCas), wherein cleavage ability of one or both strands of a double stranded DNA is inactivated and a deaminase gene are linked, was produced. These DNAs were introduced into a host yeast cell which comprises a gene to be modified. As a result, mutation could be introduced randomly within the range of several hundred nucleotides of the gene of interest including the target sequence. Compared to when a double mutant Cas protein, which do not cleave both of DNA strands in the double stranded DNA, was used, the mutation introduction efficiency increased when a mutant Cas protein which cleave of either one of the strands was used. In addition, it was clarified that the area of mutation region and variety of mutation vary depending on which of the DNA double strand is cleaved. Furthermore, mutation could be introduced extremely efficiently by targeting a plurality of regions in the target gene of interest. That is, a host cell introduced with DNA was seeded in a nonselective medium, and the sequence of the target gene of interest was examined in randomly selected colonies. As a result, introduction of mutation was confirmed in almost all colonies. It was also confirmed that genome editing can be simultaneously performed at a plurality of sites by targeting certain region in two or more target genes of interest. It was further demonstrated that the method can simultaneously introduce mutation into alleles of diploid or polyploid genomes, can introduce mutation into not only eukaryotic cells but also prokaryotic cells such as *Escherichia coli,* and is widely applicable irrespective of species. It was also found that editing of essential gene, which showed low efficiency heretofore, can be efficiently performed by transiently performing a nucleic acid base conversion reaction at a desired stage.

[0017] The present inventors have conducted further studies based on these findings and completed the present invention.

[0018] Accordingly, the present invention is as described below.

[0019] [1] A method of modifying a targeted site of a double stranded DNA, comprising a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and a nucleic acid base converting enzyme are linked, with said double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into said targeted site, without cleaving at least one strand of said double stranded DNA in the targeted site.

[0020] [2] The method of [1], wherein the nucleic acid sequence-recognizing module is selected from the group consisting of a CRISPR-Cas system wherein at least one DNA cleavage ability of Cas is inactivated, a zinc finger motif, a TAL effector and a PPR motif.

[0021] [3] The method of [1], wherein the nucleic acid sequence-recognizing module is a CRISPR-Cas system wherein at least one DNA cleavage ability of Cas is inactivated.

[0022] [4] The method of any of [1]-[3], which uses two or more kinds of nucleic acid sequence-recognizing modules each specifically binding to a different target nucleotide sequence.

[0023] [5] The method of [4], wherein the different target nucleotide sequence is present in a different gene.

[0024] [6] The method of any of [1]-[5], wherein the nucleic acid base converting enzyme is deaminase.

[0025] [7] The method of the above-mentioned [6], wherein the deaminase is AID (AICDA).

[0026] [8] The method of any of [1]- [7], wherein the double stranded DNA is contacted with the complex by introducing a nucleic acid encoding the complex into a cell having the double stranded DNA.

[0027] [9] The method of [8], wherein the cell is a prokaryotic cell.

[0028] [10] The method of [8], wherein the aforementioned cell is a eukaryotic cell.

[0029] [11] The method of [8], wherein the cell is a cell of a microorganism.

[0030] [12] The method of [8], wherein the cell is a plant cell.

[0031] [13] The method of [8], wherein the cell is an insect cell.

[0032] [14] The method of [8], wherein the cell is an animal cell.

[0033] [15] The method of [8], wherein the aforementioned cell is a cell of a vertebrate.

[0034] [16] The method of [8], wherein the cell is a mammalian cell.

[0035] [17] The method of any of [9]- [16], wherein the cell is a polyploid cell, and a site in any targeted allele on a homologous chromosome is modified.

[0036] [18] The method of any of [8]- [17], comprising a step of introducing an expression vector comprising a nucleic acid encoding the complex in a form permitting control of an expression period into the cell, and a step of inducing expression of the nucleic acid for a period necessary for stabilizing the modification of the targeted site in the double stranded DNA.

[0037] [19] The method of the above-mentioned [18], wherein the target nucleotide sequence in the double stranded DNA is present in a gene essential for the cell.

[0038] [20] A nucleic acid-modifying enzyme complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and a nucleic acid base converting enzyme are linked, which converts one or more nucleotides in the targeted site to other one or more nucleotides or deletes one or more nucleotides, or inserts one or more nucleotides into said targeted site, without cleaving at least one strand of said double stranded DNA in the targeted site.

[0039] [21] A nucleic acid encoding the nucleic acid-modifying enzyme complex of [20].

Effect of the Invention

[0040] According to the genome editing technique of the present invention, since it is not associated with insertion of a foreign DNA or double-stranded DNA breaks, the technique is superior in safety. The technique has some possibility of providing a solution in cases where conventional methods were considered as a gene recombination, and thus biologically or legally controversial. It is also theoretically possible to set a wide range of mutation introduction from a pin point of one base to several hundred bases, and the technique can also be applied to local evolution induction by

introduction of random mutation into a particular limited region, which has been almost impossible heretofore.

BRIEF DESCRIPTION OF THE DRAWINGS

[0041] FIG. **1** is a schematic illustration showing a mechanism of the genetic modification method of the present invention using the CRISPR-Cas system.

[0042] FIG. **2** shows the results of verification, by using a budding yeast, of the effect of the genetic modification method of the present invention comprising a combination of a CRISPR-Cas system and PmCDA1 deaminase from *Petromyzon marinus*.

[0043] FIG. **3** shows changes in the number of surviving cells after expression induction when a CRISPR-Cas9 system using a D10A mutant of Cas9 having a nickase activity and a deaminase, PmCDA1, are used in combination (nCas9 D10A-PmCDA1), and when conventional Cas9 having a DNA double strand cleavage ability is used.

[0044] FIG. **4** shows the results when a plurality of expression constructs are constructed such that human AID deaminase and dCas9 are linked via SH3 domain and a binding ligand thereof, wherein the express constructs are introduced into a budding yeast together with two kinds of gRNA (targeting sequences of target 4 and target 5).

[0045] FIG. **5** shows that the mutation introduction efficiency is increased by the use of Cas9 that cleaves either DNA single strand.

[0046] FIG. **6** shows that in the case where a double stranded DNA is not cleaved, the area of mutation introduction region and frequency thereof change depending on which one of the single strands is cleaved.

[0047] FIG. **7** shows that extremely high mutation introduction efficiency can be realized by targeting two regions in proximity.

[0048] FIG. **8** shows that the genetic modification method of the present invention does not require selection by marker. It was found that mutation was introduced into all colonies sequenced.

[0049] FIG. **9** shows that a plurality of sites in a genome can be simultaneously edited by the genetic modification method of the present invention. The upper panel shows the nucleotide sequence and amino acid sequence of the target site of each gene, and an arrow on the nucleotide sequence shows the target nucleotide sequence. The number at the arrow end or arrow head indicates the position of the target nucleotide sequence terminus on ORF. The lower panel shows the results of sequencing of the target site in each 5 clones of red (R) and white (W) colonies. In the sequences, the nucleotides indicated with outline characters show occurrence of base conversion. As for responsiveness to canavanine (Can^R), R shows resistance, and S shows sensitivity.

[0050] FIG. **10** shows that a mutation can be simultaneously introduced into both alleles on the homologous chromosome of diploid genome by the genetic modification method of the present invention. FIG. **10**A shows homologous mutation introduction efficiency of Ade1 gene (upper panel) and can1 gene respectively. FIG. **10**B shows that homologous mutation was actually introduced into red colony (lower panel). Also, occurrence of heterologous mutation in white colony was shown (upper panel).

[0051] FIG. **11** shows that genome editing of *Escherichia coli,* a prokaryotic cell, is possible by the genetic modification method of the present invention. FIG. **11**A is a schematic illustration showing the plasmid used. FIG. **11**B shows that a mutation (CAA→TAA) could be efficiently introduced by targeting a region in the galK gene. FIG. **11**C shows the results of sequence analysis of each two clones of the respective colonies in a nonselective medium (none), a medium containing 25 μg/ml rifampicin (Rif25) or a medium containing 50 μg/ml rifampicin (Rif50). Introduction of a mutation imparting rifampicin resistance was confirmed (upper panel). The appearance frequency of rifampicin resistance strain was estimated to be about 10% (lower panel).

[0052] FIG. **12** shows control of the edited base sites by the length of guide RNA. FIG. **12**A is a conceptual Figure of editing base site when the length of the target nucleotide sequence is 20 bases or 24 bases. FIG. **12**B shows the results of editing by targeting gsiA gene and changing the length of the target nucleotide sequence. The mutated sites are shown with bold letters, "T" and "A" show introduction of complete mutation (C→T or G→A) into the clone, "t" shows that not less than 50% of mutation (C→T) is introduced into the clone (incomplete cloning), and "c" shows that the introduction efficiency of the mutation (C→T) into the clone is less than 50%.

[0053] FIG. **13** is a schematic illustration showing a temperature sensitive plasmid for mutation introduction, which was used in Example 11.

[0054] FIG. **14** shows the protocol of mutation introduction in Example 11.

[0055] FIG. **15** shows the results of introduction of mutation into the rpoB gene in Example **11**.

[0056] FIG. **16** shows the results of introduction of mutation into the galK gene in Example 11.

DESCRIPTION OF EMBODIMENTS

[0057] The present invention provides a method of modifying a targeted site of a double stranded DNA by converting the target nucleotide sequence and nucleotides in the vicinity thereof in the double stranded DNA to other nucleotides, without cleaving at least one strand of the double stranded DNA to be modified. The method characteristically comprises a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to the target nucleotide sequence in the double stranded DNA and a nucleic acid base converting enzyme are linked, with the double stranded DNA to convert the targeted site, i.e., the target nucleotide sequence and nucleotides in the vicinity thereof, to other nucleotides.

[0058] In the present invention, the "modification" of a double stranded DNA means that a nucleotide (e.g., dC) on a DNA strand is converted to another nucleotide (e.g., dT, dA or dG), or deleted, or a nucleotide or a nucleotide sequence is inserted between certain nucleotides on the DNA strand. While the double stranded DNA to be modified is not particularly limited, it is preferably a genomic DNA. The "targeted site" of a double stranded DNA means the entire or partial "target nucleotide sequence", which a nucleic acid sequence-recognizing module specifically recognizes and binds to, or the vicinity of the target nucleotide sequence (one or both of 5' upstream and 3' downstream), and the length thereof can be appropriately adjusted between 1 base and several hundred bases according to the object.

[0059] In the present invention, the "nucleic acid sequence-recognizing module" means a molecule or molecule complex having an ability to specifically recognize

and bind to a particular nucleotide sequence (i.e., target nucleotide sequence) on a DNA strand. Binding of the nucleic acid sequence-recognizing module to a target nucleotide sequence enables a nucleic acid base converting enzyme linked to the module to specifically act on a targeted site of a double stranded DNA.

[0060] In the present invention, the "nucleic acid base converting enzyme" means an enzyme capable of converting a target nucleotide to another nucleotide by catalyzing a reaction for converting a substituent on a purine or pyrimidine ring on a DNA base to another group or atom, without cleaving the DNA strand.

[0061] In the present invention, the "nucleic acid-modifying enzyme complex" means a molecular complex comprising a complex of the above-mentioned nucleic acid sequence-recognizing module linked with a nucleic acid base converting enzyme, wherein the complex has nucleic acid base converting enzyme activity and is imparted with a particular nucleotide sequence recognition ability. The "complex" used herein encompasses not only one composed of a plurality of molecules, but also a single molecule having a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme such as a fusion protein.

[0062] The nucleic acid base converting enzyme used in the present invention is not particularly limited as long as it can catalyze the above-mentioned reaction, and examples thereof include deaminase belonging to the nucleic acid/nucleotide deaminase superfamily, which catalyzes a deamination reaction that converts an amino group to a carbonyl group. Preferable examples thereof include cytidine deaminase capable of converting cytosine or 5-methylcytosine to uracil or thymine, respectively, adenosine deaminase capable of converting adenine to hypoxanthine, guanosine deaminase capable of converting guanine to xanthine and the like. As cytidine deaminase, more preferred is activation-induced cytidine deaminase (hereinafter also referred to as AID), which is an enzyme that introduces a mutation into an immunoglobulin gene in the acquired immunity of vertebrate or the like.

[0063] While the origin of nucleic acid base converting enzyme is not particularly limited, for example, PmCDA1 (*Petromyzon marinus* cytosine deaminase 1) from *Petromyzon marinus,* or AID (Activation-induced cytidine deaminase; AICDA) from mammal (e.g., human, swine, bovine, horse, monkey etc) can be used. The base sequence and amino acid sequence of CDS of PmCDA1 are shown in SEQ ID NOs: 1 and 2, respectively, and the base sequence and amino acid sequence of CDS of human AID are shown in SEQ ID NOs: 3 and 4, respectively.

[0064] A target nucleotide sequence in a double stranded DNA to be recognized by the nucleic acid sequence-recognizing module in the nucleic acid-modifying enzyme complex of the present invention is not particularly limited as long as the module specifically binds to any sequence in the double stranded DNA. The length of the target nucleotide sequence only needs to be sufficient for specific binding of the nucleic acid sequence-recognizing module. For example, when mutation is introduced into a particular site in the genomic DNA of a mammal, it is not less than 12 nucleotides, preferably not less than 15 nucleotides, more preferably not less than 17 nucleotides, according to the genome size thereof. While the upper limit of the length is not particularly limited, it is preferably not more than 25 nucleotides, more preferably not more than 22 nucleotides.

[0065] As the nucleic acid sequence-recognizing module in the nucleic acid-modifying enzyme complex of the present invention, CRISPR-Cas system wherein at least one DNA cleavage ability of Cas is inactivated (CRISPR-mutant Cas), zinc finger motif, TAL effector and PPR motif and the like, as well as a fragment containing a DNA binding domain of a protein that specifically binds to DNA such as restriction enzyme, transcription factor, RNA polymerase or the like, and not having a DNA double strand cleavage ability and the like can be used, but the module is not limited thereto. Preferably, the modules include CRISPR-mutant Cas, zinc finger motif, TAL effector, PPR motif and the like.

[0066] A zinc finger motif is constructed by linking 3-6 different Cys2His2 type zinc finger units (1 finger recognizes about 3 bases), and can recognize a target nucleotide sequence of 9-18 bases. A zinc finger motif can be produced by a known method such as Modular assembly method (*Nat Biotechnol* (2002) 20: 135-141), OPEN method (*Mol Cell* (2008) 31: 294-301), CoDA method (*Nat Methods* (2011) 8: 67-69), *Escherichia coli* one-hybrid method (*Nat Biotechnol* (2008) 26:695-701) and the like. The above-mentioned patent document 1 can be referred to as for the detail of the zinc finger motif production.

[0067] A TAL effector has a module repeat structure with about 34 amino acids as a unit, and the 12th and 13th amino acid residues (called RVD) of one module determine the binding stability and base specificity. Since each module is highly independent, TAL effector specific to a target nucleotide sequence can be produced by simply linking the modules. For TAL effector, production methods utilizing an open resource (REAL method (*Curr Protoc Mol Biol* (2012) Chapter 12: Unit 12.15), FLASH method (*Nat Biotechnol* (2012) 30: 460-465), and Golden Gate method (*Nucleic Acids Res* (2011) 39: e82) etc) have been established, and a TAL effector for a target nucleotide sequence can be designed relatively easily. The above-mentioned patent document 2 can be referred to as for the detail of the production of TAL effector.

[0068] PPR motif is constructed such that a particular nucleotide sequence is recognized by a series of PPR motifs each consisting of 35 amino acids and recognizing one nucleic acid base, and recognizes a target base only by 1, 4 and ii(−2) amino acids of each motif. Motif configuration has no dependency, and is free of interference of motifs on both sides. Therefore, similar to TAL effector, a PPR protein specific to the target nucleotide sequence can be produced by simply linking PPR motifs. The above-mentioned patent document 4 can be referred to as for the detail of the production of PPR motif.

[0069] When a fragment of a restriction enzyme, transcription factor, RNA polymerase or the like is used, since the DNA binding domains of these proteins are well known, a fragment containing said domain and not having a DNA double strand cleavage ability can be easily designed and constructed.

[0070] Any of the above-mentioned nucleic acid sequence-recognizing module can be provided as a fusion protein with the above-mentioned nucleic acid base converting enzyme, or a protein binding domain such as SH3 domain, PDZ domain, GK domain, GB domain and the like and a binding partner thereof may be fused with a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme, respectively, and provided as a protein complex via an interaction of the domain and a binding

partner thereof. Alternatively, a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme may be each fused with intein, and they can be linked by ligation after protein synthesis.

[0071] The nucleic acid-modifying enzyme complex of the present invention containing a complex (including fusion protein), wherein a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme are linked, may be contacted with a double stranded DNA as an enzyme reaction in a cell-free system. In view of the main object of the present invention, it is desirable to perform the contact by introducing a nucleic acid encoding the complex into a cell having the double stranded DNA of interest (e.g., genomic DNA).

[0072] Therefore, the nucleic acid sequence-recognizing module and the nucleic acid base converting enzyme are preferably prepared as a nucleic acid encoding a fusion protein thereof, or as nucleic acids encoding each of them in a form capable of forming a complex in a host cell after translation into a protein by utilizing a binding domain, intein or the like. The nucleic acid here may be a DNA or an RNA. When it is a DNA, it is preferably a double stranded DNA, and provided in the form of an expression vector disposed under regulation of a functional promoter in a host cell. When it is an RNA, it is preferably a single stranded RNA.

[0073] Since the complex of the present invention wherein a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme are linked, is not associated with double-stranded DNA breaks (DSB), genome editing with low toxicity is possible, and the genetic modification method of the present invention can be applied to a wide range of biological materials. Therefore, the cells into which nucleic acid encoding nucleic acid sequence-recognizing module and/or nucleic acid base converting enzyme is introduced can encompass cells of any species, from cells of microorganisms, such as bacterium,such as *Escherichia coli* and the like which are prokaryotes, such as yeast and the like which are lower eukaryotes, to cells of higher eukaryotes such as insect, plant and the like, and cells of vertebrates including mammals such as human and the like.

[0074] A DNA encoding a nucleic acid sequence-recognizing module such as zinc finger motif, TAL effector, PPR motif and the like can be obtained by any method mentioned above for each module. A DNA encoding a sequence-recognizing module of restriction enzyme, transcription factor, RNA polymerase and the like can be cloned by, for example, synthesizing an oligoDNA primer covering a region encoding a desired part of the protein (part containing DNA binding domain) based on the cDNA sequence information thereof, and amplifying by the RT-PCR method using, the total RNA or mRNA fraction prepared from the protein-producing cells as a template.

[0075] A DNA encoding a nucleic acid base converting enzyme can also be cloned similarly by synthesizing an oligoDNA primer based on the cDNA sequence information thereof, and amplifying by the RT-PCR method using, the total RNA or mRNA fraction prepared from the enzyme-producing cells as a template. For example, a DNA encoding PmCDA1 of *Petromyzon marinus* can be cloned by designing suitable primers for the upstream and downstream of CDS based on the cDNA sequence (accession No. EF094822) registered in the NCBI database, and cloning from mRNA *Petromyzon marinus* by the RT-PCR method. A DNA encoding human AID can be cloned by designing suitable primers for the upstream and downstream of CDS based on the cDNA sequence (accession No. AB040431) registered in the NCBI database, and cloning from, for example, mRNA from human lymph node by the RT-PCR method.

[0076] The cloned DNA may be directly, or after digestion with a restriction enzyme when desired, or after addition of a suitable linker and/or a nuclear localization signal (each organelle transfer signal when the target double stranded DNA of interest is mitochondria or chloroplast DNA), ligated with a DNA encoding a nucleic acid sequence-recognizing module to prepare a DNA encoding a fusion protein. Alternatively, a DNA encoding a nucleic acid sequence-recognizing module, and a DNA encoding a nucleic acid base converting enzyme may be each fused with a DNA encoding a binding domain or a binding partner thereof, or both DNAs may be fused with a DNA encoding a separation intein, whereby the nucleic acid sequence-recognizing conversion module and the nucleic acid base converting enzyme are translated in a host cell to form a complex. In these cases, a linker and/or a nuclear localization signal can be linked to a suitable position of one of or both DNAs when desired.

[0077] A DNA encoding a nucleic acid sequence-recognizing module and a DNA encoding a nucleic acid base converting enzyme can be obtained by chemically synthesizing the DNA strand, or by linking partly overlapping synthesized oligoDNA short strands by utilizing the PCR method and the Gibson Assembly method to construct a DNA encoding the full length thereof. The advantage of constructing a full-length DNA by chemical synthesis or a combination of PCR method or Gibson Assembly method is that the codon used can be designed in CDS full-length according to the host into which the DNA is introduced. In the expression of a heterologous DNA, the protein expression level is expected to increase by converting the DNA sequence thereof to a codon which is highly frequently used in the host organism. As the data of codon use frequency in host used, for example, the genetic code use frequency database (www.kazusa.or.jp/codon/index.html) disclosed in the home page of Kazusa DNA Research Institute can be used, or documents showing the codon use frequency in each host may be referred to. By reference to the obtained data and the DNA sequence to be introduced, codons showing low use frequency in the host from those used for the DNA sequence may be converted to a codon coding the same amino acid and showing high use frequency.

[0078] An expression vector containing a DNA encoding a nucleic acid sequence-recognizing module and/or a nucleic acid base converting enzyme can be produced, for example, by linking the DNA to the downstream of a promoter in a suitable expression vector.

[0079] As the expression vector, plasmids from *Escherichia coli* (e.g., pBR322, pBR325, pUC12, pUC13); plasmids from *Bacillus subtilis* (e.g., pUB110, pTP5, pC194); plasmids from yeast (e.g., pSH19, pSH15); insect cell expression plasmids (e.g., pFast-Bac); animal cell expression plasmids (e.g., pA1-11, pXT1, pRc/CMV, pRc/RSV, pcDNAI/Neo); bacteriophages such as λ phage and the like; insect virus vectors such as baculovirus and the like (e.g., BmNPV, AcNPV); animal virus vectors such as retrovirus, vaccinia virus, adenovirus and the like, are used.

[0080] As the promoter, any promoter appropriate for a host used for gene expression can be used. In a conventional method involving DSB, since the survival rate of the host cell sometimes decreases markedly due to the toxicity, it is desirable to increase the number of cells by the start of the induction by using an inductive promoter. However, since sufficient cell proliferation can also be achieved by expressing the nucleic acid-modifying enzyme complex of the present invention, a constitutive promoter can also be used without limitation.

[0081] For example, when the host is an animal cell, SRa promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Moloney mouse leukemia virus) LTR, HSV-TK (simple herpes virus thymidine kinase) promoter and the like are used. Of these, CMV promoter, SRa promoter and the like are preferable.

[0082] When the host is *Escherichia coli,* trp promoter, lac promoter, recA promoter, λP_L promoter, Ipp promoter, T7 promoter and the like are preferable.

[0083] When the host is genus Bacillus, SPO1 promoter, SPO2 promoter, penP promoter and the like are preferable.

[0084] When the host is a yeast, Gal/10 promoter, PHO5 promoter, PGK promoter, GAP promoter, ADH promoter and the like are preferable.

[0085] When the host is an insect cell, polyhedrin promoter, P10 promoter and the like are preferable.

[0086] When the host is a plant cell, CaMV35S promoter, CaMV19S promoter, NOS promoter and the like are preferable.

[0087] As the expression vector, besides those mentioned above, one containing enhancer, splicing signal, terminator, polyA addition signal, a selection marker such as drug resistance gene, auxotrophic complementary gene and the like, replication origin and the like on demand can be used.

[0088] An RNA encoding a nucleic acid sequence-recognizing module and/or a nucleic acid base converting enzyme can be prepared by, for example, transcription to mRNA in an in vitro transcription system known per se by using a vector encoding DNA encoding the above-mentioned nucleic acid sequence-recognizing module and/or a nucleic acid base converting enzyme as a template.

[0089] A complex of a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme can be intracellularly expressed by introducing an expression vector containing a DNA encoding a nucleic acid sequence-recognizing module and/or a nucleic acid base converting enzyme into a host cell, and culturing the host cell.

[0090] As the host, genus *Escherichia,* genus *Bacillus,* yeast, insect cell, insect, animal cell and the like are used.

[0091] As the genus *Escherichia, Escherichia coli* K12-DH1 [*Proc. Natl. Acad. Sci. USA,* 60, 160 (1968)], *Escherichia coli* JM103 [*Nucleic Acids Research,* 9, 309 (1981)], *Escherichia coli* JA221 [*Journal of Molecular Biology,* 120, 517 (1978)], *Escherichia coli* HB101 [*Journal of Molecular Biology,* 41, 459 (1969)], *Escherichia coli* C600 [*Genetics,* 39, 440 (1954)] and the like are used.

[0092] As the genus *Bacillus, Bacillus subtilis* M1114 [Gene, 24, 255 (1983)], *Bacillus subtilis* 207-21 [*Journal of Biochemistry,* 95, 87 (1984)] and the like are used.

[0093] As the yeast, *Saccharomyces cerevisiae* AH22, AH22R$^-$, NA87-11A, DKD-5D, 20B-12, *Schizosaccharomyces pombe* NCYC1913, NCYC2036, *Pichia pastoris KM*71 and the like are used.

[0094] As the insect cell when the virus is AcNPV, cells of established line from cabbage armyworm larva (*Spodoptera frugiperda* cell; Sf cell), MG1 cells from the mid-intestine of *Trichoplusia ni,* High Five™ cells from an egg of *Trichoplusia ni,* cells from *Mamestra brassicae,* cells from *Estigmena acrea* and the like are used. When the virus is BmNPV, cells of established line from *Bombyx mori* (*Bombyx mori* N cell; BmN cell) and the like are used as insect cells. As the Sf cell, for example, Sf9 cell (ATCC CRL1711), Sf21 cell [all above, *In Vivo,* 13, 213-217 (1977)] and the like are used.

[0095] As the insect, for example, larva of *Bombyx mori, Drosophila,* cricket and the like are used [*Nature,* 315, 592 (1985)].

[0096] As the animal cell, cell lines such as monkey COS-7 cell, monkey Vero cell, Chinese hamster ovary (CHO) cell, dhfr gene-deficient CHO cell, mouse L cell, mouse AtT-20 cell, mouse myeloma cell, rat GH3 cell, human FL cell and the like, pluripotent stem cells such as iPS cell, ES cell and the like of human and other mammals, and primary cultured cells prepared from various tissues are used. Furthermore, zebrafish embryo, Xenopus oocyte and the like can also be used.

[0097] As the plant cell, suspend cultured cells, callus, protoplast, leaf segment, root segment and the like prepared from various plants (e.g., grain such as rice, wheat, corn and the like, product crops such as tomato, cucumber, egg plant and the like, garden plants such as carnation, *Eustoma russeffianum* and the like, experiment plants such as tobacco, *arabidopsis thaliana* and the like) are used.

[0098] All the above-mentioned host cells may be haploid (monoploid), or polyploid (e.g., diploid, triploid, tetraploid and the like). In the conventional mutation introduction methods, mutation is, in principle, introduced into only one homologous chromosome to produce a heterologous genotype. Therefore, the desired feature is not expressed unless it is a dominant mutation, and making it homologous inconveniently requires labor and time. In contrast, according to the present invention, since mutations can be introduced into all alleles on the homologous chromosome in the genome, desired feature can be expressed in a single generation even in the case of recessive mutation (FIG. **10**), which is extremely useful since the problem of the conventional method can be solved.

[0099] An expression vector can be introduced by a known method (e.g., lysozyme method, competent method, PEG method, $CaCl_2$ coprecipitation method, electroporation method, the microinjection method, the particle gun method, lipofection method, *Agrobacterium* method and the like) according to the kind of the host.

[0100] *Escherichia coli* can be transformed according to the methods described in, for example, *Proc. Natl. Acad. Sci. USA,* 69, 2110 (1972), *Gene,* 17, 107 (1982) and the like.

[0101] A vector can be introduced into the genus *Bacillus* according to the methods described in, for example, *Molecular & General Genetics,* 168, 111 (1979) and the like.

[0102] A vector can be introduced into a yeast according to the methods described in, for example, *Methods in Enzymology,* 194, 182-187 (1991), *Proc. Natl. Acad. Sci. USA,* 75, 1929 (1978) and the like.

[0103] A vector can be introduced into an insect cell and an insect according to the methods described in, for example, *Bio/Technology,* 6, 47-55 (1988) and the like.

[0104] A vector can be introduced into an animal cell according to the methods described in, for example, *Cell Engineering* additional volume 8, New Cell Engineering Experiment Protocol, 263-267 (1995) (published by Shujunsha), and *Virology,* 52, 456 (1973).

[0105] A cell introduced with a vector can be cultured according to a known method according to the kind of the host.

[0106] For example, when *Escherichia coli* or genus *Bacillus* is cultured, a liquid medium is preferable as a medium used for the culture. The medium preferably contains a carbon source, nitrogen source, inorganic substance and the like necessary for the growth of the transformant. Examples of the carbon source include glucose, dextrin, soluble starch, sucrose and the like; examples of the nitrogen source include inorganic or organic substances such as ammonium salts, nitrate salts, corn steep liquor, peptone, casein, meat extract, soybean cake, potato extract and the like; and examples of the inorganic substance include calcium chloride, sodium dihydrogen phosphate, magnesium chloride and the like. The medium may contain yeast extract, vitamins, growth promoting factor and the like. The pH of the medium is preferably about 5-about 8.

[0107] As a medium for culturing *Escherichia coli,* for example, M9 medium containing glucose, casamino acid [*Journal of Experiments in Molecular Genetics,* 431-433, Cold Spring Harbor Laboratory, New York 1972] is preferable. Where necessary, for example, agents such as 3β-indolylacrylic acid may be added to the medium to ensure an efficient function of a promoter. *Escherichia coli* is cultured at generally about 15-about 43° C. Where necessary, aeration and stirring may be performed.

[0108] The genus *Bacillus* is cultured at generally about 30-about 40° C. Where necessary, aeration and stirring may be performed.

[0109] Examples of the medium for culturing yeast include Burkholder minimum medium [*Proc. Natl. Acad. Sci. USA,* 77, 4505 (1980)], SD medium containing 0.5% casamino acid [*Proc. Natl. Acad. Sci. USA,* 81, 5330 (1984)] and the like. The pH of the medium is preferably about 5-about 8. The culture is performed at generally about 20° C.-about 35° C. Where necessary, aeration and stirring may be performed.

[0110] As a medium for culturing an insect cell or insect, for example, Grace's Insect Medium [*Nature,* 195, 788 (1962)] containing an additive such as inactivated 10% bovine serum and the like as appropriate and the like are used. The pH of the medium is preferably about 6.2-about 6.4. The culture is performed at generally about 27° C. Where necessary, aeration and stirring may be performed.

[0111] As a medium for culturing an animal cell, for example, minimum essential medium (MEM) containing about 5-about 20% of fetal bovine serum [*Science,* 122, 501 (1952)], Dulbecco's modified Eagle medium (DMEM) [*Virology,* 8, 396 (1959)], RPMI 1640 medium [*The Journal of the American Medical Association,* 199, 519 (1967)], 199 medium [*Proceeding of the Society for the Biological Medicine,* 73, 1 (1950)] and the like are used. The pH of the medium is preferably about 6-about 8. The culture is performed at generally about 30° C.-about 40° C. Where necessary, aeration and stirring may be performed.

[0112] As a medium for culturing a plant cell, for example, MS medium, LS medium, B5 medium and the like are used. The pH of the medium is preferably about 5-about 8. The culture is performed at generally about 20° C.-about 30° C. Where necessary, aeration and stirring may be performed.

[0113] As mentioned above, a complex of a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme, i.e., nucleic acid-modifying enzyme complex, can be expressed intracellularly.

[0114] An RNA encoding a nucleic acid sequence-recognizing module and/or a nucleic acid base converting enzyme can be introduced into a host cell by microinjection method, lipofection method and the like. RNA introduction can be performed once or multiple times (e.g., 2-5 times) at suitable intervals.

[0115] When a complex of a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme is expressed by an expression vector or RNA molecule introduced into the cell, the nucleic acid sequence-recognizing module specifically recognizes and binds to a target nucleotide sequence in the double stranded DNA (e.g., genomic DNA) of interest and, due to the action of the nucleic acid base converting enzyme linked to the nucleic acid sequence-recognizing module, base conversion occurs in the sense strand or antisense strand of the targeted site (whole or partial target nucleotide sequence or appropriately adjusted within several hundred bases including the vicinity thereof) and a mismatch occurs in the double stranded DNA (e.g., when cytidine deaminase such as PmCDA1, AID and the like is used as a nucleic acid base converting enzyme, cytosine on the sense strand or antisense strand at the targeted site is converted to uracil to cause U:G or G:U mismatch). When the mismatch is not correctly repaired, and when repaired such that a base of the opposite strand forms a pair with a base of the converted strand (T-A or A-T in the above-mentioned example), or when another nucleotide is further substituted (e.g., U→A, G) or when one to several dozen bases are deleted or inserted during repair, various mutations are introduced.

[0116] As for zinc finger motif, production of many actually functional zinc finger motifs is not easy, since production efficiency of a zinc finger that specifically binds to a target nucleotide sequence is not high and selection of a zinc finger having high binding specificity is not easy. While TAL effector and PPR motif have a high degree of freedom of target nucleic acid sequence recognition as compared to zinc finger motif, a problem remains in the efficiency since a large protein needs to be designed and constructed every time according to the target nucleotide sequence.

[0117] In contrast, since the CRISPR-Cas system recognizes the sequence of double stranded DNA of interest by a guide RNA complementary to the target nucleotide sequence, any sequence can be targeted by simply synthesizing an oligoDNA capable of specifically forming a hybrid with the target nucleotide sequence.

[0118] Therefore, in a more preferable embodiment of the present invention, a CRISPR-Cas system wherein at least one DNA cleavage ability of Cas is inactivated (CRISPR-mutant Cas) is used as a nucleic acid sequence-recognizing module.

[0119] FIG. **1** is a schematic illustration showing the double stranded DNA modification method of the present invention using CRISPR-mutant Cas as a nucleic acid sequence-recognizing module.

[0120] The nucleic acid sequence-recognizing module of the present invention using CRISPR-mutant Cas is provided as a complex of an RNA molecule consisting of a guide

RNA complementary to the target nucleotide sequence and tracrRNA necessary for recruiting mutant Cas protein, and a mutant Cas protein.

[0121] The Cas protein used in the present invention is not particularly limited as long as it belongs to the CRISPR system, and is preferably Cas9. Examples of Cas9 include, but are not limited to, Cas9 (SpCas9 from *Streptococcus pyogenes,* Cas9 (StCas9) from *Streptococcus thermophilus* and the like, preferably SpCas9. As a mutant Cas used in the present invention, either a Cas having cleavage ability of both strands of the double stranded DNA is inactivated, or a Cas having nickase activity wherein only one of the cleavage ability of only one of the strands is inactivated, can be used. For example, in the case of SpCas9, a Dl OA mutant wherein the 10th Asp residue is converted to an Ala residue and lacking cleavage ability of a strand opposite to the strand forming a complementary strand with a guide RNA, or H840A mutant wherein the 840th His residue is converted to an Ala residue and lacking cleavage ability of strand complementary to guide RNA, or a double mutant thereof can be used, and another mutant Cas can be used similarly.

[0122] A nucleic acid base converting enzyme is provided as a complex with mutant Cas by a method similar to the linking scheme with the above-mentioned zinc finger and the like. Alternatively, a nucleic acid base converting enzyme and mutant Cas can also be linked by utilizing RNA scaffold with RNA aptamers MS2F6, PP7 and the like and binding proteins thereto. Guide RNA forms a complementary strand with the target nucleotide sequence, mutant Cas is recruited by the attached tracrRNA and mutant Cas recognizes DNA cleavage site recognition sequence PAM (protospacer adjacent motif) (when SpCas9 is used, PAM is 3 bases of NGG (N is any base), and, theoretically, can target any position on the genome). One or both DNAs cannot be cleaved, and, due to the action of the nucleic acid base converting enzyme linked to the mutant Cas, base conversion occurs in the targeted site (appropriately adjusted within several hundred bases including whole or partial target nucleotide sequence) and a mismatch occurs in the double stranded DNA. When the mismatch is not correctly repaired, and when repaired such that a base of the opposite strand forms a pair with a base of the converted strand, or when another nucleotide is further converted or when one to several dozen bases are deleted or inserted during repair, various mutations are introduced (see, e.g., FIG. **2**).

[0123] Even when CRISPR-mutant Cas is used as a nucleic acid sequence-recognizing module, a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme are introduced, desirably in the form of a nucleic acid encoding same, into a cell having a double stranded DNA of interest, similar to when zinc finger and the like are used as a nucleic acid sequence-recognizing module.

[0124] A DNA encoding Cas can be cloned by a method similar to the above-mentioned method for a DNA encoding a nucleic acid base converting enzyme, from a cell producing the enzyme. A mutant Cas can be obtained by introducing a mutation to convert an amino acid residue of the part important for the DNA cleavage activity (e.g., 10th Asp residue and 840th His residue for Cas9, though not limited thereto) to another amino acid, into a DNA encoding cloned Cas, by a site specific mutation induction method known per se.

[0125] Alternatively, a DNA encoding mutant Cas can also be constructed as a DNA having codon usage suitable for expression in a host cell to be used, by a method similar to those mentioned above for a DNA encoding a nucleic acid sequence-recognizing module and a DNA encoding a nucleic acid base converting enzyme, and in a combination with chemical synthesis or PCR method or Gibson Assembly method. For example, CDS sequence and amino acid sequence optimized for the expression of SpCas9 in eukaryotic cells are shown in SEQ ID NOs: 5 and 6. In the sequence shown in SEQ ID NO: 5, when "A" is converted to "C" in base No. 29, a DNA encoding a Dl OA mutant can be obtained, and when "CA" is converted to "GC" in base Nos. 2518-2519, a DNA encoding an H840A mutant can be obtained.

[0126] A DNA encoding a mutant Cas and a DNA encoding a nucleic acid base converting enzyme may be linked to allow for expression as a fusion protein, or designed to be separately expressed using a binding domain, intein or the like, and form a complex in a host cell via protein-protein interaction or protein ligation.

[0127] The obtained DNA encoding a mutant Cas and/or a nucleic acid base converting enzyme can be inserted into the downstream of a promoter of an expression vector similar to the one mentioned above, according to the host.

[0128] On the other hand, a DNA encoding guide RNA and tracrRNA can be obtained by designing an oligoDNA sequence linking guide RNA sequence complementary to the target nucleotide sequence and known tracrRNA sequence (e.g., gttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtggtgctttt; SEQ ID NO: 7) and chemically synthesizing using a DNA/RNA synthesizer.

[0129] While the length of the guide RNA sequence is not particularly limited as long as it can specifically bind to a target nucleotide sequence, for example, it is 15-30 nucleotides, preferably 18-24 nucleotides.

[0130] While a DNA encoding guide RNA and tracrRNA can also be inserted into an expression vector similar to the one mentioned above, according to the host. As the promoter, pol III promoter (e.g., SNR6, SNR52, SCR1, RPR1, U6, H1 promoter etc.) and terminator (e.g., T_6 sequence) are preferably used.

[0131] An RNA encoding mutant Cas and/or a nucleic acid base converting enzyme can be prepared by, for example, transcription to mRNA in an in vitro transcription system known per se by using a vector encoding the above-mentioned mutant Cas and/or DNA encoding a nucleic acid base converting enzyme as a template.

[0132] Guide RNA-tracrRNA can be obtained by designing an oligoDNA sequence in which a sequence complementary to the target nucleotide sequence and known tracrRNA sequence are linked, and chemically synthesizing using a DNA/RNA synthesizer.

[0133] A DNA or RNA encoding mutant Cas and/or a nucleic acid base converting enzyme, guide RNA-tracrRNA or a DNA encoding same can be introduced into a host cell by a method similar to the above, according to the host.

[0134] Since conventional artificial nuclease accompanies Double-stranded DNA breaks (DSB), inhibition of growth and cell death assumedly caused by disordered cleavage (off-target cleavage) of chromosome may occur by targeting a sequence in the genome. The effect thereof is particularly fatal for many microorganisms and prokaryotes, and prevents applicability. In the present invention, mutation is introduced not by DNA cleavage but by a conversion

reaction of the substituent on the DNA base (particularly deamination reaction), and therefore, drastic reduction of toxicity can be realized. In fact, as shown in the comparison tests using a budding yeast as a host in the below-mentioned Examples, when Cas9 having a conventional type of DSB activity is used, the number of surviving cells decreases by induction of expression, whereas it was confirmed that the cells continued to grow and the number of surviving cells increased by the technique of the present invention using a combination of mutant Cas and a nucleic acid base converting enzyme in combination (FIG. **3**).

[0135] The modification of the double stranded DNA in the present invention does not preclude occurrence of cleavage of the double stranded DNA in a site other than the targeted site (appropriately adjusted within several hundred bases including whole or partial target nucleotide sequence). However, one of the greatest advantages of the present invention is avoidance of toxicity by off-target cleavage, which is generally applicable to any species. In one preferable embodiment, therefore, the modification of the double stranded DNA in the present invention is not associated with cleavage of DNA strand not only in a targeted site of a selected double stranded DNA but in other sites.

[0136] As shown in the below-mentioned Examples, when Cas having a nickase activity capable of cleaving only one of the strands of the double stranded DNA is used as a mutant Cas (FIG. **5**), the mutation introduction efficiency increases as compared to when mutant Cas which is incapable of cleaving both strands is used. Therefore, for example, besides a nucleic acid sequence-recognizing module and a nucleic acid base converting enzyme, linking a protein having a nickase activity, thereby cleaving only a DNA single strand in the vicinity of the target nucleotide sequence, the mutation introduction efficiency can be improved while avoiding the strong toxicity of DSB.

[0137] Furthermore, a comparison of the effects of mutant Cas having two kinds of nickase activity of cleaving different strand reveals that using one of the mutant Cas results in mutated sites accumulating near the center of the target nucleotide sequence, and using another mutant Cas results in various mutations which are randomly introduced into region of several hundred bases from the target nucleotide sequence (FIG. **6**). Therefore, by selecting a strand to be cleaved by the nickase, a mutation can be introduced into a particular nucleotide or nucleotide region at a pinpoint, or various mutations can be randomly introduced into a comparatively wide range, which can be properly adopted according to the object. For example, when the former technique is applied to genetically diseased iPS cell, a cell transplantation therapeutic agent with a lower risk of rejection can be produced by repairing mutation of the pathogenic gene in an iPS cell produced from the patients' own cell, and differentiating the cell into the somatic cell of interest.

[0138] Example 7 and the subsequent Examples mentioned below show that a mutation can be introduced into a particular nucleotide almost at a pinpoint. For pinpoint introduction of a mutation into a desired nucleotide, the target nucleotide sequence should be set to show certain regularity of the positional relationship between a nucleotide desired to be introduced with a mutation and the target nucleotide sequence. CRISPR-Cas system is used as a nucleic acid sequence-recognizing module and AID is used as a nucleic acid base converting enzyme, the target nucleotide sequence can be designed such that C (or G in the opposite strand) into which a mutation is desired to be introduced is at 2-5 nucleotides from the 5'-end of the target nucleotide sequence. As mentioned above, the length of the guide RNA sequence can be appropriately determined to fall between 15-30 nucleotides, preferably 18-24 nucleotides. Since the guide RNA sequence is a sequence complementary to the target nucleotide sequence, the length of the target nucleotide sequence changes when the length of the guide RNA sequence is changed; however, the regularity that a mutation is likely to be introduced into C or G at 2-5 nucleotides from the 5'-end irrespective of the length of the nucleotide, is maintained (FIG. **12**). Therefore, by appropriately determining the length of the target nucleotide sequence (guide RNA as a complementary strand thereof), the site of a base into which a mutation can be introduced can be shifted. As a result, restriction by DNA cleavage site recognition sequence PAM (NGG) can also be removed, and the degree of freedom of mutation introduction becomes higher.

[0139] As shown in the below-mentioned Examples, when sequence-recognizing modules are produced corresponding to a plurality of target nucleotide sequences in proximity, and simultaneously used, the mutation introduction efficiency drastically increases relative to when a single nucleotide sequence is used as a target (FIG. **7**). As the effect thereof, similar mutation induction is realized even when both target nucleotide sequences partly overlap or when the both are apart by about 600 bp. It can occur when both target nucleotide sequences are in the same direction (target nucleotide sequences are present on the same strand) (FIG. **7**), and when they are opposed (target nucleotide sequences are present on each strand of double stranded DNA) (FIG. **4**).

[0140] As shown in the below-mentioned Examples, the genome sequence modification method of the present invention can introduce mutation into almost all cells in which the nucleic acid-modifying enzyme complex of the present invention has been expressed, by selecting a suitable target nucleotide sequence (FIG. **8**). Thus, insertion and selection of a selection marker gene, which are essential in the conventional genome editing, are not necessary. This dramatically facilitates and simplifies gene manipulation and extends the applicability to crop breeding and the like since a recombinant organism with foreign DNA is not produced.

[0141] Since the genome sequence modification method of the present invention shows extremely high mutation introduction efficiency, and does not require selection by markers, a plurality of DNA regions at completely different positions can be modified as targets (FIG. **9**). Therefore, in one preferable embodiment of the present invention, two or more kinds of nucleic acid sequence-recognizing modules that specifically bind to different target nucleotide sequences (which may be present in one target gene of interest, or two or more different target genes of interest, which may be present on the same chromosome or different chromosomes) can be used. In this case, each one of these nucleic acid sequence-recognizing modules and nucleic acid base converting enzyme form a nucleic acid-modifying enzyme complex. Here, a common nucleic acid base converting enzyme can be used. For example, when CRISPR-Cas system is used as a nucleic acid sequence-recognizing module, a common complex of a Cas protein and a nucleic acid base converting enzyme (including fusion protein) is

used, and two or more kinds of chimeric RNAs of tracrRNA and each of two or more guide RNAs that respectively form a complementary strand with a different target nucleotide sequences are produced and used as guide RNA-tracrRNAs. On the other hand, when zinc finger motif, TAL effector and the like are used as nucleic acid sequence-recognizing modules, for example, a nucleic acid base converting enzyme can be fused with a nucleic acid sequence-recognizing module that specifically binds to a different target nucleotide.

[0142] To express the nucleic acid-modifying enzyme complex of the present invention in a host cell, as mentioned above, an expression vector containing a DNA encoding the nucleic acid-modifying enzyme complex, or an RNA encoding the nucleic acid-modifying enzyme complex is introduced into a host cell. For efficient introduction of mutation, it is desirable to maintain an expression of nucleic acid-modifying enzyme complex at a given level or above for not less than a given period. From such aspect, introduction of an expression vector autonomously replicatable in a host cell (plasmid etc.) is reliable. However, since the plasmid etc. are foreign DNAs, they are preferably removed rapidly after successful introduction of mutation. Therefore, although it varies depending on the kind of host cell and the like, for example, the introduced plasmid is desirably removed from the host cell after a lapse of 6 hr-2 days from the introduction of an expression vector by using various plasmid removal methods which are well known in the art.

[0143] Alternatively, as long as sufficient expression of a nucleic acid-modifying enzyme complex for the introduction of mutation is achieved, it is also preferable to introduce mutation into the target double stranded DNA of interest by transient expression by using an expression vector without autonomous replicatability in a host cell (e.g., vector lacking replication origin that functions in a host cell and/or gene encoding protein necessary for replication etc.) or RNA.

[0144] Expression of target gene is suppressed while the nucleic acid-modifying enzyme complex of the present invention is expressed in a host cell to perform a nucleic acid base conversion reaction. Therefore, it was difficult to directly edit a gene essential for the survival of the host cell as a target gene (result in side effects such as growth inhibition of host, unstable mutation introduction efficiency, mutation of site different from target and the like). In the present invention, direct editing of an essential gene has been successfully and efficiently realized by causing a nucleic acid base conversion reaction at a desired stage, and transiently expressing the nucleic acid-modifying enzyme complex of the present invention in a host cell for a period necessary for stabilizing the modification of the targeted site. While the period necessary for a nucleic acid base conversion reaction and stabilizing the modification of the targeted site varies depending on the kind of the host cell, culture conditions and the like, host cells of 2-20 generations are generally considered to be necessary. For example, when the host cell is a yeast or bacterium (e.g., *Escherichia coli*), expression of a nucleic acid-modifying enzyme complex needs to be induced for 5-10 generations. Those of ordinary skill in the art can appropriately determine a preferable expression induction period based on the doubling time of the host cell under culture conditions used. For example, when a budding yeast is subjected to liquid culture in a 0.02% galactose inducer medium, the expression induction period is, for example, 20-40 hr. The expression induction period of the nucleic acid encoding the nucleic acid-modifying enzyme complex of the present invention may be extended beyond the above-mentioned "period necessary for establishing the modification of the targeted site" to the extent not causing side effects to the host cell.

[0145] As a means for transiently expressing the nucleic acid-modifying enzyme complex of the present invention at a desired stage for a desired period, a method comprising producing a construct (expression vector) containing a nucleic acid encoding the nucleic acid-modifying enzyme complex (a DNA encoding a guide RNA-tracrRNA and a DNA encoding a mutant Cas and nucleic acid base substitution enzyme in the case of CRISPR-Cas system), in a manner that the expression period can be controlled, and introducing the construct into a host cell can be used. The "manner that the expression period can be controlled" is specifically, for example, a nucleic acid encoding the nucleic acid-modifying enzyme complex of the present invention placed under regulation of an inducible regulatory region. While the "inducible regulatory region" is not particularly limited, it is, for example, an operon of a temperature sensitive (ts) mutation repressor and an operator regulated thereby in microorganism cells of bacterium (e.g., *Escherichia coli*), yeast and the like. Examples of the ts mutation repressor include, but are not limited to, ts mutation of cl repressor from λ phage. In the case of λ phage cl repressor (ts), it is linked to an operator to suppress expression of gene in the downstream at not more than 30° C. (e.g., 28° C.). At a high temperature of not less than 37° C. (e.g., 42° C.), it is dissociated from the operator to allow for induction of gene expression (FIGS. **13** and **14**). Therefore, the period when the expression of the target gene is suppressed can be minimized by culturing a host cell introduced with a nucleic acid encoding nucleic acid-modifying enzyme complex generally at not more than 30° C., raising the temperature to not less than 37° C. at an appropriate stage, performing culture for a given period to carry out a nucleic acid base conversion reaction and, after introduction of mutation into the target gene, rapidly lowering the temperature to not more than 30° C. Thus, even when an essential gene for the host cell is targeted, it can be efficiently edited while suppressing the side effects (FIG. **15**).

[0146] When temperature sensitive mutation is utilized, for example, a temperature sensitive mutant of a protein necessary for autonomous replication of a vector is included in a vector containing a DNA encoding the nucleic acid-modifying enzyme complex of the present invention. As a result, autonomous replication becomes impossible rapidly after expression of the nucleic acid-modifying enzyme complex, and the vector naturally falls off during the cell division. Examples of the temperature sensitive mutant protein include, but are not limited to, a temperature sensitive mutant of Rep101 ori necessary for the replication of pSC101 ori. Rep101 ori (ts) acts on pSC101 ori to enable autonomous replication of plasmid at not more than 30° C. (e.g., 28° C.), but loses function at not less than 37° C. (e.g., 42° C.), and plasmid cannot replicate autonomously. Therefore, a combined use with cl repressor (ts) of the above-mentioned A phage simultaneously enables transient expression of the nucleic acid-modifying enzyme complex of the present invention, and removal of the plasmid.

[0147] On the other hand, when a higher eukaryotic cell such as animal cell, insect cell, plant cell and the like is used as a host cell, a DNA encoding the nucleic acid-modifying

enzyme complex of the present invention is introduced into a host cell under regulation of an inducible promoter (e.g., metallothionein promoter (induced by heavy metal ion), heat shock protein promoter (induced by heat shock), Tet-ON/Tet-OFF system promoter (induced by addition or removal of tetracycline or a derivative thereof), steroid-responsive promoter (induced by steroid hormone or a derivative thereof) etc.), the induction substance is added to the medium (or removed from the medium) at an appropriate stage to induce expression of the nucleic acid-modifying enzyme complex, culture is performed for a given period to carry out a nucleic acid base conversion reaction and, introduction of mutation into the target gene, transient expression of the nucleic acid-modifying enzyme complex can be realized.

[0148] In Prokaryotic cells such as *Escherichia coli* and the like, inducible promoters can also be used. Examples of such inducible promoters include, but are not limited to, lac promoter (induced by IPTG), cspA promoter (induced by cold shock), araBAD promoter (induced by arabinose) and the like.

[0149] Alternatively, the above-mentioned inducible promoters can also be utilized as a vector removal mechanism when higher eukaryotic cells such as animal cell, insect cell, plant cell and the like are used as a host cell. That is, a vector is loaded with a replication origin that can function in a host cell, and a nucleic acid encoding a protein necessary for replication thereof (e.g., SV40 ori and large T antigen, oriP and EBNA-1 etc. for animal cells), and the expression of the nucleic acid encoding the protein is regulated by the above-mentioned inducible promoter. As a result, while the vector is autonomously replicatable in the presence of an induction substance, when the induction substance is removed, autonomous replication does not occur, and the vector naturally falls off during cell division (conversely, autonomous replication becomes impossible by the addition of tetracycline and doxycycline in the case of Tet-OFF system vector).

[0150] The present invention is explained in the following by referring to Examples, which are not to be construed as limitative.

EXAMPLE

[0151] In the below-mentioned Examples 1-6, experiments were performed as follows.

<Cell Line, Culture, Transformation, and Expression Induction>

[0152] Budding yeast Saccharomyces cerevisiae BY4741 strain (requiring leucine and uracil) was cultured in a standard YPDA medium or SD medium with a Dropout composition satisfying the auxotrophicity. The culture performed was standing culture in an agar plate or shaking culture in a liquid medium between 25° C. and 30° C. Transformation was performed by a lithium acetate method, and selection was made in SD medium matching appropriate auxotrophicity. For expression induction by galactose, after preculture overnight in an appropriate SD medium, culture in SR medium overnight with carbon source changed from 2% glucose to 2% raffinose, and further culture in SGal medium for 3 hr to about two nights with carbon source changed to 0.2-2% galactose were conducted for expression induction.

[0153] For the measurement of the number of surviving cells and Can1 mutation rate, a cell suspension was appropriately diluted, and applied on SD plate medium and SD-Arg+60 mg/I Canavanine plate medium or SD+300 mg/I Canavanine plate medium, and the number of colonies that emerge 3 days later was counted as the number of surviving cells. Using the number of surviving colonies in SD plate as the total number of cells, and the number of surviving colonies in Canavanine plate as the number of resistant mutant strain, the mutation rate was calculated and evaluated. The site of mutation introduction was identified by amplifying DNA fragments containing the target gene region of each strain by a colony PCR method, performing DNA sequencing, and performing an alignment analysis based on the sequence of Saccharomyces Genome Database (www.yeastgenome.org).

<Nucleic Acid Operation>

[0154] DNA was processed or constructed by any of PCR method, restriction enzyme treatment, ligation, Gibson Assembly method, and artificial chemical synthesis. For plasmid, as the yeast/•*Escherichia coli* shuttle vector, pRS315 for leucine selection and pRS426 for uracil selection were used as the backbone. Plasmid was amplified by *Escherichia coli* line XL-10 gold or DH5α, and introduced into yeast by the lithium acetate method.

<Construct>

[0155] For inducible expression, budding yeast pGa1/10 (SEQ ID NO: 8), which is a bidirectional promoter inducible by galactose, was used. At the downstream of a promoter, a nuclear localization signal (ccc aag aag aag agg aag gtg; SEQ ID NO: 9(PKKKRV; encoding SEQ ID NO: 10)) was added to Cas9 gene ORF from *Streptococcus pyogenes* having a codon optimized for eukaryon expression (SEQ ID NO: 5) and ORF (SEQ ID NO: 1 or 3) of deaminase gene (PmCDA1 from *Petromyzon marinus* or hAID from human) was ligated via a linker sequence, and expressed as a fusion protein. As a linker sequence, GS linker (repeat of ggt gga gga ggt tct; SEQ ID NO: 11 (encoding GGGGS; SEQ ID NO: 12)), Flag® tag (gac tat aag gac cacgac gga gac tac aag gat cat gat att gat tac aaa gac gat gac gat aag; SEQ ID NO: 13 (encoding DYKDHDGDYKDHDIDYKDDDDK; SEQ ID NO: 14)), Strep-tag® (tgg agc cac ccg cag ttc gaa aaa; SEQ ID NO: 15 (encoding WSHPQFEK; SEQ ID NO: 16)), and other domains are selected and used in combination. Here, particularly, 2xGS, SH3 domain (SEQ ID NO: 17 and 18), and Flag® tag were ligated and used. As a terminator, ADH1 terminator from budding yeast (SEQ ID NO: 19) and Top2 terminator (SEQ ID NO: 20) were ligated. In the domain integration method, Cas9 gene ORF was ligated to SH3 domain via 2xGS linker to give one protein, deaminase was added with SH3 ligand sequence (SEQ ID NOs: 21 and 22) as another protein, and they were ligated to Ga1/10 promoter on both sides. And they were simultaneously expressed. These were incorporated into pRS315 plasmid.

[0156] In Cas9, mutation to convert the 10th aspartic acid to alanine (D10A, corresponding DNA sequence mutation a29c) and mutation to convert the 840th histidine to alanine (H840A, corresponding DNA sequence mutation ca2518gc) were introduced to remove cleavage ability of either side of DNA strand.

[0157] gRNA as a chimeric structure with tracrRNA (from Streptococcus pyogenes; SEQ ID NO: 7) was disposed between SNR52 promoter (SEQ ID NO: 23) and Sup4 terminator (SEQ ID NO: 24), and incorporated into pRS426 plasmid. As gRNA target base sequence, CAN1 gene ORF, 187-206 (gatacgttctctatggagga; SEQ ID NO: 25) (target 1), 786-805 (ttggagaaacccaggtgcct; SEQ ID NO: 26) (target 3), 793-812 (aacccaggtgcctggggtcc; SEQ ID NO: 27) (target 4), 563-582 (ttggccaagtcattcaattt; SEQ ID NO: 28) (target 2) and complementary strand sequence of 767-786 (ataacg-gaatccaactgggc; SEQ ID NO: 29) (target 5r) were used. For simultaneous expression of a plurality of targets, using a sequence from a promoter to a terminator as one set, and a plurality of the sets were incorporated into the same plasmid. They were introduced into cells along with Cas9-deaminase expression plasmid, intracellularly expressed, and a complex of gRNA-tracrRNA and Cas9-deaminase was formed.

Example 1: Modification of Genome Sequence by Linking DNA Sequence Recognition Ability of CRISPR-Cas to Deaminase PmCDA1

[0158] To test the effect of genome sequence modification technique of the present invention by utilizing deaminase and CRISPR-Cas nucleic acid sequence recognition ability, introduction of mutation into CAN1 gene encoding canavanine transporter, whose gene deficit results in canavanine-resistance, was attempted. As gRNA, a sequence complementary to 187-206 (target 1) of CAN1 gene ORF was used, a chimeric RNA expression vector obtained by linking thereto tracrRNA from *Streptococcus pyogenes,* and a vector expressing a protein obtained by fusing dCas9 with impaired nuclease activity by introducing mutations (D10A and H840A) into Cas9 (SpCas9) from *Streptococcus pyogenes* with PmCDA1 from *Petromyzon marinus* as deaminase were constructed, introduced into the budding yeast by the lithium acetate method, and coexpressed. The results are shown in FIG. **2**. When cultured on a canavanine-containing SD plate, only the cells subjected to introduction and expression of gRNA-tracrRNA and dCas9-PmCDA1 formed colony. The resistant colony was picked up and the sequence of CAN1 gene region was determined. As a result, it was confirmed that a mutation was introduced into the target nucleotide sequence (target 1) and the vicinity thereof.

Example 2: Drastic Reduction of side Effects•Toxicity

[0159] In conventional Cas9 and other artificial nucleases (ZFN, TALEN), inhibition of growth and cell death assumedly caused by disordered cleavage of chromosome occur by targeting a sequence in the genome. The effect thereof is particularly fatal for many microorganisms and prokaryotes, and prevents applicability.

[0160] Therefore, to verify the safety and cell toxicity of the genome sequence modification technique of the present invention, a comparative test with conventional CRISPR-Cas9 was performed. Using sequences (targets 3, 4) in the CAN1 gene as gRNA target, the surviving cells were counted immediately after the start of expression induction by galactose and at 6 hr after the induction based on the colony forming ability on an SD plate. The results are shown in FIG. **3**. In conventional Cas9, the growth was inhibited and cell death was induced, which decreased the number of surviving cells. In contrast, by the present technique (nCas9 D10A-PmCDA1), the cells could continue to grow, and the number of surviving cells drastically increased.

Example 3: Use of Different Linking Scheme

[0161] Whether mutation can be introduced into a targeted gene even when Cas9 and deaminase are not used as a fusion protein but when a nucleic acid-modifying enzyme complex is formed via a binding domain and a ligand thereof was examined. As Cas9, dCas9 used in Example 1 was used and human AID instead of PmCDA1 was used as deaminase. SH3 domain was fused with the former, and a binding ligand thereof was fused with the latter to produce various constructs shown in FIG. **4**. In addition, sequences (target 4,5r) in the CAN1 gene were used as gRNA targets. These constructs were introduced into a budding yeast. As a result, even when dCas9 and deaminase were linked via the binding domain, mutation was efficiently introduced into the targeted site of the CAN1 gene (FIG. **4**). The mutation introduction efficiency was remarkably improved by introducing a plurality of binding domains into dCas9. The main site of mutation introduction was 782nd (g782c) of ORF.

Example 4: High Efficiency and Changes in Mutation Pattern by Use of Nickase

[0162] In the same manner as in Example 1 except that D10A mutant nCas9 (D10A) that cleaves only a strand complementary to gRNA, or H840A mutant nCas9 (H840A) that cleaves only a strand opposite to a strand complementary to gRNA was used instead of dCas9, mutation was introduced into the CAN1 gene, and the sequence in the CAN1 gene region of the colony generated on a canavanine-containing SD plate was examined. It was found that the efficiency increases in the former (nCas9 (D10A)) as compared to dCas9 (FIG. **5**), and the mutation gathers in the center of the target sequence (FIG. **6**). Therefore, this method enables pinpoint introduction of mutation. On the other hand, it was found in the latter (nCas9 (H840A)) that a plurality of random mutations were introduced into a region of several hundred bases from the targeted nucleotide (FIG. **6**) along with an increase in the efficiency as compared to dCas9 (FIG. **5**).

[0163] Similar remarkable introduction of mutation could be confirmed even when the target nucleotide sequence was changed. In this genome editing system using CRISPR-Cas9 system and cytidine deaminase, it was confirmed as shown in Table 1 that cytosine present within the range of about 2-5 bp from the 5'-side of the target nucleotide sequence (20 bp) were preferentially deaminated. Therefore, by setting the target nucleotide sequence based on this regularity and further combining with nCas9 (D10A), precise genome editing of 1 nucleotide unit is possible. On the other hand, a plurality of mutations can be simultaneously inserted within the range of about several hundred bp in the vicinity of the target nucleotide sequence by using nCas9 (H840A). Furthermore, site specificity may possibly be further varied by changing the linking scheme of deaminase.

[0164] These results show that the kind of Cas9 protein can be changed properly according to the object.

TABLE 1

position of CAN1 gene ORF	sequence (SEQ ID NO:)	site of main mutation introduction
187-206 (target 1)	Gatacgttctcta tggagga (25)	c191a, g226t
563-582 (target 2)	Ttggccaagtcat tcaattt (28)	cc567at, c567del
786-805 (target 3) and 793-812 (target 4)	Ttggagaaaccca ggtgcct (26) Aacccaggtgcct ggggtcc (27)	cc795tt, cc796tt
767-786 (complementary strand) (target 5r)	Ataacggaatcca actgggc (29)	g782c

Example 5: Efficiency Increases Synergistically by Targeting a Plurality of DNA Sequences in Proximity

[0165] Efficiency drastically increased by simultaneously using a plurality of targets in proximity rather than a single target (FIG. **7**). In fact, 10-20% of cells had canavanine-resistant mutation (targets 3, 4). In the Figure, gRNA1 and gRNA2 target target 3 and target 4, respectively. As deaminase, PmCDA1 was used. The effect thereof was confirmed to occur not only when the sequences partly overlapped (targets 3, 4), but also when they were apart by about 600 bp (targets 1, 3). The effect was found both when the DNA sequences were in the same direction (targets 3, 4) and opposing (targets 4, 5) (FIG. **4**).

Example 6: Genetic Modification not Requiring Selection Marker

[0166] As for the cells (Targets 3, 4) in which target 3 and target 4 were targeted in Example 5, 10 colonies were randomly selected from those grown on a non-selected (canavanine-free) plate (SD plate not containing Leu and Ura) and the sequences of the CAN1 gene region were determined. As a result, mutation was introduced into the targeted site of the CAN1 gene in all examined colonies (FIG. **8**). That is, editing can be expected in almost all expressed cells by selecting a suitable target sequence according to the present invention. Therefore, insertion of a marker gene and selection, which are essential for the conventional gene manipulation, are not necessary. This dramatically facilitates and simplifies gene manipulation and extends the applicability to crop breeding and the like since a recombinant organism with foreign DNA is not produced.

[0167] In the following Examples, experiment techniques shared by Examples 1-6 were performed in the same manner as above.

Example 7: Simultaneous Editing of a Plurality of Sites (Different Gene)

[0168] In a general gene manipulation method, mutation of only one site is generally achieved by one operation due to various restrictions. Thus, whether a simultaneous mutation operation of a plurality of sites is possible using the method of the present invention was tested.

[0169] Using the ORF of positions 3 to 22 of Ade1 gene of budding yeast BY4741 strain as the first target nucleotide sequence (Ade1 target 5:GTCAATTACGAAGACTGAAC; SEQ ID NO: 30), and the ORF of positions 767-786 (complementary strand) of Can1 gene as the second target nucleotide sequence (Can1 target8 (786-767; ATAACG-GAATCCAACTGGGC; SEQ ID NO: 29), both DNAs encoding chimeric RNAs of two kinds of gRNAs each containing a nucleotide sequence complementary thereto and tracrRNA (SEQ ID NO: 7) were placed on the same plasmid (pRS426), and introduced into BY4741 strain together with plasmid nCas9 D10A-PmCDA1 containing a nucleic acid encoding a fusion protein of mutant Cas9 and PmCDA1, and expressed, and introduction of mutation into the both genes was verified. The cells were cultured in an SD drop-out medium (uracil and leucine deficient; SD-UL) as a base, which maintains plasmid. The cells were appropriately diluted, applied on SD-UL and canavaine addition medium and allowed to form a colony. After 2 days of culture at 28° C., colonies were observed, and the incidence of red colony due to Ade1 mutation, and the survival rate in a canavanine medium were respectively counted. The results are shown in Table 2.

TABLE 2

medium	incidence of red colony	survival rate in Canavanine medium (Can)	red colony and Can survival rate
SD-UL	0.54 ± 0.04		
+canavanine	0.64 ± 0.14	0.51 ± 0.15	0.31 ± 0.04

[0170] As a phenotype, the proportion of introduction of mutation into both Ade1 gene and Can1 gene was high and about 31%.

[0171] Then, a colony on an SD-UL medium was subjected to PCR amplification followed by sequencing. Regions containing ORF of each of Ade1 and Can1 were amplified, and sequence information of about 500 b sequences surrounding the target sequence was obtained. To be specific, 5 red colonies and 5 white colonies were analyzed to find conversion of the 5th C of Ade1 gene ORF to G in all red colonies and the 5th C to T in all white colonies (FIG. **9**). While the mutation rate of the target is 100%, as the mutation rate in light of the object of gene destruction, the desired mutation rate is 50% since the 5th C needs to be changed to G to be a stop codon. Similarly, as for the Can1 gene, mutation was confirmed in the 782nd G of ORF in all clones (FIG. **9**); however, since only the mutation to C affords canavanine-resistance, the desired mutation rate is 70%. Desired mutations in both genes were simultaneously obtained in 40% clones (4 clones out of 10 clones) by investigation, and practically high efficiency was obtained.

Example 8: Editing of Polyploid Genome

[0172] Many organisms have diploid or polyploid genome. In the conventional mutation introduction methods, mutation is, in principle, introduced into only one homologous chromosome to produce a heterologous geno-type. Therefore, desired feature is not obtained unless it is a dominant mutation, and making it homologous requires labor and time. Thus, whether the technique of the present

invention can introduce mutation into all target alleles on the homologous chromosome in the genome was tested.

[0173] That is, simultaneous editing of Ade1 and Can1 genes was performed in budding yeast YPH501 strain as a diploid strain. The phenotype of these gene mutations (red colony and canavanine-resistant) is a recessive phenotype, and therefore, these phenotypes do not appear unless both mutations of homologous gene (homologous mutation) are introduced.

[0174] Using the ORF of positions 1173-1154 (complementary strand) of Ade1 gene (Ade1 target 1: GTCAATAGGATCCCCTTTT; SEQ ID NO: 31) or of positions 3-22 (Ade1 target 5: GTCAATTACGAAGACTGAAC; SEQ ID NO: 30) as the first target nucleotide sequence, and the ORF of positions 767-786 (complementary strand) of Can1 gene as the second target nucleotide sequence (Can1 target8: ATAACGGAATCCAACTGGGC; SEQ ID NO: 29), both DNAs encoding chimeric RNAs of two kinds of gRNAs each containing a nucleotide sequence complementary thereto and tracrRNA (SEQ ID NO: 7) were placed on the same plasmid (pRS426), and introduced into BY4741 strain together with plasmid nCas9 D10A-PmCDA1 containing a nucleic acid encoding a fusion protein of mutant Cas9 and PmCDA1, and expressed, and introduction of mutation into each gene was verified.

[0175] As a result of colony count, it was found that each characteristic of phenotype could be obtained at a high probability (40% - 70%) (FIG. **10**A).

[0176] To confirm mutation, Ade1 target region of each of white colony and red colony was sequenced to confirm overlapping of sequence signals indicating heterologous mutation in the target site of white colony (FIG. **10**B, upper panel, G and T signals overlap at ↓). Phenotype was confirmed to be absent in colony with heterologous mutation. On the other hand, homologous mutation free of overlapping signal was confirmed in red colony (FIG. **10**B, lower panel, T signal at ↓).

Example 9: Genome Editing in *Escherichia coli*

[0177] In this Example, it is demonstrated that this technique effectively functions in *Escherichia coli,* which is a representative bacterium model organism. Particularly, conventional nuclease type genome editing technique is fatal for bacteria, and the application is difficult. Thus, the superiority of this technique is emphasized. In combination with yeast, which is an eukaryote model cell, it is shown that this technique is widely applicable to any species irrespective of prokaryon and eukaryon.

[0178] Amino acid mutation of DlOA and H840A were introduced (dCas9) into *Streptococcus pyogenes* Cas9 gene containing bidirectional promoter region, and a construct to be expressed as a fusion protein with PmCDA1 via a linker sequence was constructed, and chimeric gRNAs encoding a sequence complementary to each of the target nucleotide sequences was simultaneously included in a plasmid (full-length nucleotide sequence is shown in SEQ ID NO: 32, in which sequence, a sequence complementary to each of the target sequences is introduced into the site of n_{20}) (FIG. **11**A).

[0179] First, the ORF of positions 426-445 (T CAA TGG GCT AAC TAC GTT C; SEQ ID NO: 33) of *Escherichia coli* galK gene was introduced as a target nucleotide sequence into a plasmid, various *Escherichia coli* strains (XL10-gold, DH5a, MG1655, BW25113) were transformed with the plasmid by calcium method or electroporation method, SOC medium was added, recovery culture was performed overnight, plasmid carrying cells were selected from ampicillin-containing LB medium, and colony was formed. Introduction of mutation was verified by direct-sequence from colony PCR. The results are shown in FIG. **11**B.

[0180] Independent colony (1-3) was selected randomly, and sequence was analyzed. As a result, the 427-position C of ORF was converted to T (clones 2, 3) at a probability of not less than 60%, and the occurrence of gene destruction generating a stop codon (TAA) was confirmed.

[0181] Then, with a complementary sequence (5'-GGTCCATAAACTGAGACAGC-3'; SEQ ID NO: 34) of 1530-1549 base region of rpoB gene ORF, which is an essential gene, as a target, particular point mutation was introduced by a method similar to the above-mentioned method to try to impart rifampicin-resistant function to *Escherichia coli.* The sequences of colonies selected in a nonselective medium (none), a 25 μg/ml rifampicin (Rif25) and 50 μg/ml rifampicin (Rif50)-containing medium were analyzed. As a result, it was confirmed that conversion of the 1546-position G of ORF to A introduced amino acid mutation from Asp(GAC) to Asn(AAC), and rifampicin-resistance was imparted (FIG. **11**C, upper panel). A 10-fold dilution series of the cell suspension after transformation treatment was spotted on a nonselective medium (none), a 25 μg/ml rifampicin (Rif25) and 50 μg/ml rifampicin (Rif50)-containing medium and cultured. As a result, it is estimated that rifampicin-resistant strain was obtained at about 10% frequency (FIG. **11**C, lower panel).

[0182] As shown above, by this technique, a new function can be added by particular point mutation, rather than simple gene destruction. This technique is superior since essential gene is directly edited.

Example 10: Adjustment of editing base site by gRNA length

[0183] Conventionally, the gRNA length relative to a target nucleotide sequence was 20b as basic, and cytosine (or guanine in opposite strand) in a site of 2-5b from the 5'-terminus thereof (15-19b upstream of PAM sequence) is used as a mutation target. Whether expression of different gRNA length can shift the site of the base to be the target was examined (FIG. **12**A).

[0184] Experimental Example performed on *Escherichia coli* is shown in FIG. **12**B. A site containing many cytosines on *Escherichia coli* genome was searched for, and the experiment was performed using gsiA gene, which is a putative ABC-transporter. Substituted cytosine was examined while changing the length of the target to 24 bp, 22 bp, 20 bp, 18 bp to find that the 898th, 899th cytosine was substituted by thymine in the case of 20 bp (standard length). When the target site is longer than 20 bp, the 896th and 897th cytosines were also substituted, and when the target site was shorter, the 900th and 901st cytosines were also substituted. In fact, the target site could be shifted by changing the length of the gRNA.

Example 11: Development of Temperature Dependent Genome Editing Plasmid

[0185] A plasmid that induces expression of the nucleic acid-modifying enzyme complex of the present invention

under high temperature conditions was designed. While optimizing efficiency by limitatively controlling the expression state, reduction of side effects (growth inhibition of host, unstable mutation introduction efficiency, mutation of site different from target and the like) was aimed. Simultaneously, a simultaneous and easy removal of plasmid after editing was intended by combining a mechanism for ceasing the replication of plasmid at a high temperature. The detail of the experiment is shown below.

[0186] With temperature sensitive plasmid pSC101-Rep101 system (sequence of pSC101 ori is shown in SEQ ID NO: 35, and sequence of temperature sensitive Rep101 is shown in SEQ ID NO: 36) as a backbone, temperature sensitive A repressor (c1857) system was used for expression induction. For genome editing, G113E mutation imparting RecA resistance was introduced into A repressor, to ensure normal function even under SOS response (SEQ ID NO: 37). dCas9-PmCDA1 (SEQ ID NO: 38) was ligated to Right Operator (SEQ ID NO: 39), and gRNA (SEQ ID NO: 40) was ligated to the downstream of Left Operator (SEQ ID NO: 41) to regulate the expression (full-length nucleotide sequence of the constructed expression vector is shown in SEQ ID NO: 42). During culture at not more than 30° C., transcription of gRNA and expression of dCas9-PmCDA1 are suppressed, and the cells can grow normally. When cultured at not less than 37° C., transcription of gRNA and expression of dCas9-PmCDA1 are induced, and replication of plasmid is suppressed simultaneously. Therefore, a nucleic acid-modifying enzyme complex necessary for genome editing is transiently supplied, and plasmid can be removed easily after editing (FIG. **13**).

[0187] Specific protocol of the base substitution is shown in FIG. **14**.

[0188] The culture temperature for plasmid construction is set at around 28° C., and an *Escherichia coli* colony retaining the desired plasmid is first established. Then, the colony is directly used, or after plasmid extraction when the strain is changed, transformation with the target strain is performed again, and the obtained colony is used. Liquiud culture at 28° C. is performed overnight. Thereafter, the colony is diluted with the medium, induction culture is performed at 42° C. for 1 hr to overnight, the cell suspension is appropriately diluted and spread or spotted on a plate to acquire a single colony.

[0189] As a verification experiment, point mutation introduction into essential gene rpoB was performed. When rpoB, which is one of the RNA polymerase-constituting factors, is deleted or its function is lost, the *Escherichia coli* will not survive. On the other hand, it is known that resistance to antibiotic rifampicin (Rif) is acquired when point mutation is entered at a particular site. Therefore, aiming at such introduction of point mutation, a target site is selected and assay was performed.

[0190] The results are shown in FIG. **15**. In the upper left panel, the left shows an LB (chloramphenicol addition) plate, and the right shows a rifampicin-added LB (chloramphenicol addition) plate, and samples with or without chloramphenicol were prepared and cultured at 28° C. or 42° C. When cultured at 28° C., the rate of Rif resistance is low; however, when cultured at 42° C., rifampicin resistance was obtained with extremely high efficiency. When the colonies (non-selection) obtained on LB were sequenced by 8 colonies, the 1546th guanine (G) was substituted by adenine (A) in not less than 60% of the strain cultured at 42° C. (lower and upper left panels). It is clear that the base is also completely substituted in actual sequence spectrum (lower right panel).

[0191] Similarly, base substitution of galK, which is one of the factors involved in the galactose metabolism, was performed. Since metabolism of 2-deoxy-galactose (2DOG), which is an analogue of galactose, by galK is fatal to *Escherichia coli,* this was used as a selection method. Target site was set such that missense mutation is induced in target 8, and that stop codon is entered in target 12 (FIG. **16** lower right).

[0192] The results are shown in FIG. **16**. In the upper left and lower left panels, the left shows an LB (chloramphenicol addition) plate, and the right shows a 2-DOG-added LB (chloramphenicol addition) plate, and samples with or without chloramphenicol were prepared and cultured at 28° C. or 42° C. In target 8, colony was produced only slightly on a 2-DOG addition plate (upper left panel), 3 colonies on LB (red frame) were sequenced to determine that the 61st cytosine (C) was substituted by thymine (T) in all colonies (upper right). This mutation is assumed to be insufficient to lose function of galK. On the other hand, in target 12, colony was obtained on 2-DOG addition plate by culture at 28° C. and 42° C. (lower left panel). 3 colonies on LB were sequenced to determine that the 271st cytosine was substituted by thymine in all colonies (lower right). It was shown that mutation can be also introduced stably and highly efficiently in such different targets.

[0193] The contents disclosed in any publication cited herein, including patents and patent applications, are hereby incorporated in their entireties by reference, to the extent that they have been disclosed herein.

[0194] This application is based on patent application Nos. 2014-43348 and 2014-201859 filed in Japan (filing dates: Mar. 5, 2014 and Sep. 30, 2014, respectively), the contents of which are incorporated in full herein.

INDUSTRIAL APPLICABILITY

[0195] The present invention makes it possible to safely introduce site specific mutation into any species without insertion of a foreign DNA or double-stranded DNA breaks. It is also possible to set a wide range of mutation introduction from a pin point of one base to several hundred bases, and the technique can also be applied to topical evolution induction by introduction of random mutation into a particular restricted region, which has been almost impossible heretofore, and is extremely useful.

```
SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 95

<210> SEQ ID NO 1
<211> LENGTH: 624
```

-continued

```
<212> TYPE: DNA
<213> ORGANISM: Petromyzon marinus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(624)

<400> SEQUENCE: 1

atg acc gac gct gag tac gtg aga atc cat gag aag ttg gac atc tac       48
Met Thr Asp Ala Glu Tyr Val Arg Ile His Glu Lys Leu Asp Ile Tyr
1               5                   10                  15

acg ttt aag aaa cag ttt ttc aac aac aaa aaa tcc gtg tcg cat aga       96
Thr Phe Lys Lys Gln Phe Phe Asn Asn Lys Lys Ser Val Ser His Arg
            20                  25                  30

tgc tac gtt ctc ttt gaa tta aaa cga cgg ggt gaa cgt aga gcg tgt      144
Cys Tyr Val Leu Phe Glu Leu Lys Arg Arg Gly Glu Arg Arg Ala Cys
        35                  40                  45

ttt tgg ggc tat gct gtg aat aaa cca cag agc ggg aca gaa cgt ggc      192
Phe Trp Gly Tyr Ala Val Asn Lys Pro Gln Ser Gly Thr Glu Arg Gly
    50                  55                  60

att cac gcc gaa atc ttt agc att aga aaa gtc gaa gaa tac ctg cgc      240
Ile His Ala Glu Ile Phe Ser Ile Arg Lys Val Glu Glu Tyr Leu Arg
65                  70                  75                  80

gac aac ccc gga caa ttc acg ata aat tgg tac tca tcc tgg agt cct      288
Asp Asn Pro Gly Gln Phe Thr Ile Asn Trp Tyr Ser Ser Trp Ser Pro
                85                  90                  95

tgt gca gat tgc gct gaa aag atc tta gaa tgg tat aac cag gag ctg      336
Cys Ala Asp Cys Ala Glu Lys Ile Leu Glu Trp Tyr Asn Gln Glu Leu
            100                 105                 110

cgg ggg aac ggc cac act ttg aaa atc tgg gct tgc aaa ctc tat tac      384
Arg Gly Asn Gly His Thr Leu Lys Ile Trp Ala Cys Lys Leu Tyr Tyr
        115                 120                 125

gag aaa aat gcg agg aat caa att ggg ctg tgg aac ctc aga gat aac      432
Glu Lys Asn Ala Arg Asn Gln Ile Gly Leu Trp Asn Leu Arg Asp Asn
    130                 135                 140

ggg gtt ggg ttg aat gta atg gta agt gaa cac tac caa tgt tgc agg      480
Gly Val Gly Leu Asn Val Met Val Ser Glu His Tyr Gln Cys Cys Arg
145                 150                 155                 160

aaa ata ttc atc caa tcg tcg cac aat caa ttg aat gag aat aga tgg      528
Lys Ile Phe Ile Gln Ser Ser His Asn Gln Leu Asn Glu Asn Arg Trp
                165                 170                 175

ctt gag aag act ttg aag cga gct gaa aaa cga cgg agc gag ttg tcc      576
Leu Glu Lys Thr Leu Lys Arg Ala Glu Lys Arg Arg Ser Glu Leu Ser
            180                 185                 190

att atg att cag gta aaa ata ctc cac acc act aag agt cct gct gtt      624
Ile Met Ile Gln Val Lys Ile Leu His Thr Thr Lys Ser Pro Ala Val
        195                 200                 205


<210> SEQ ID NO 2
<211> LENGTH: 208
<212> TYPE: PRT
<213> ORGANISM: Petromyzon marinus

<400> SEQUENCE: 2

Met Thr Asp Ala Glu Tyr Val Arg Ile His Glu Lys Leu Asp Ile Tyr
1               5                   10                  15

Thr Phe Lys Lys Gln Phe Phe Asn Asn Lys Lys Ser Val Ser His Arg
            20                  25                  30

Cys Tyr Val Leu Phe Glu Leu Lys Arg Arg Gly Glu Arg Arg Ala Cys
        35                  40                  45
```

-continued

```
Phe Trp Gly Tyr Ala Val Asn Lys Pro Gln Ser Gly Thr Glu Arg Gly
    50                  55                  60

Ile His Ala Glu Ile Phe Ser Ile Arg Lys Val Glu Glu Tyr Leu Arg
65                  70                  75                  80

Asp Asn Pro Gly Gln Phe Thr Ile Asn Trp Tyr Ser Ser Trp Ser Pro
                85                  90                  95

Cys Ala Asp Cys Ala Glu Lys Ile Leu Glu Trp Tyr Asn Gln Glu Leu
            100                 105                 110

Arg Gly Asn Gly His Thr Leu Lys Ile Trp Ala Cys Lys Leu Tyr Tyr
        115                 120                 125

Glu Lys Asn Ala Arg Asn Gln Ile Gly Leu Trp Asn Leu Arg Asp Asn
    130                 135                 140

Gly Val Gly Leu Asn Val Met Val Ser Glu His Tyr Gln Cys Cys Arg
145                 150                 155                 160

Lys Ile Phe Ile Gln Ser Ser His Asn Gln Leu Asn Glu Asn Arg Trp
                165                 170                 175

Leu Glu Lys Thr Leu Lys Arg Ala Glu Lys Arg Arg Ser Glu Leu Ser
            180                 185                 190

Ile Met Ile Gln Val Lys Ile Leu His Thr Thr Lys Ser Pro Ala Val
        195                 200                 205


<210> SEQ ID NO 3
<211> LENGTH: 600
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(600)

<400> SEQUENCE: 3

atg gac agc ctc ttg atg aac cgg agg aag ttt ctt tac caa ttc aaa      48
Met Asp Ser Leu Leu Met Asn Arg Arg Lys Phe Leu Tyr Gln Phe Lys
1               5                   10                  15

aat gtc cgc tgg gct aag ggt cgg cgt gag acc tac ctg tgc tac gta      96
Asn Val Arg Trp Ala Lys Gly Arg Arg Glu Thr Tyr Leu Cys Tyr Val
            20                  25                  30

gtg aag agg cgt gac agt gct aca tcc ttt tca ctg gac ttt ggt tat     144
Val Lys Arg Arg Asp Ser Ala Thr Ser Phe Ser Leu Asp Phe Gly Tyr
        35                  40                  45

ctt cgc aat aag aac ggc tgc cac gtg gaa ttg ctc ttc ctc cgc tac     192
Leu Arg Asn Lys Asn Gly Cys His Val Glu Leu Leu Phe Leu Arg Tyr
    50                  55                  60

atc tcg gac tgg gac cta gac cct ggc cgc tgc tac cgc gtc acc tgg     240
Ile Ser Asp Trp Asp Leu Asp Pro Gly Arg Cys Tyr Arg Val Thr Trp
65                  70                  75                  80

ttc acc tcc tgg agc ccc tgc tac gac tgt gcc cga cat gtg gcc gac     288
Phe Thr Ser Trp Ser Pro Cys Tyr Asp Cys Ala Arg His Val Ala Asp
                85                  90                  95

ttt ctg cga ggg aac ccc tac ctc agt ctg agg atc ttc acc gcg cgc     336
Phe Leu Arg Gly Asn Pro Tyr Leu Ser Leu Arg Ile Phe Thr Ala Arg
            100                 105                 110

ctc tac ttc tgt gag gac cgc aag gct gag ccc gag ggg ctg cgg cgg     384
Leu Tyr Phe Cys Glu Asp Arg Lys Ala Glu Pro Glu Gly Leu Arg Arg
        115                 120                 125

ctg cac cgc gcc ggg gtg caa ata gcc atc atg acc ttc aaa gat tat     432
Leu His Arg Ala Gly Val Gln Ile Ala Ile Met Thr Phe Lys Asp Tyr
```

-continued

```
    130                 135                 140

ttt tac tgc tgg aat act ttt gta gaa aac cat gaa aga act ttc aaa      480
Phe Tyr Cys Trp Asn Thr Phe Val Glu Asn His Glu Arg Thr Phe Lys
145                 150                 155                 160

gcc tgg gaa ggg ctg cat gaa aat tca gtt cgt ctc tcc aga cag ctt      528
Ala Trp Glu Gly Leu His Glu Asn Ser Val Arg Leu Ser Arg Gln Leu
                165                 170                 175

cgg cgc atc ctt ttg ccc ctg tat gag gtt gat gac tta cga gac gca      576
Arg Arg Ile Leu Leu Pro Leu Tyr Glu Val Asp Asp Leu Arg Asp Ala
            180                 185                 190

ttt cgt act ttg gga ctt ctc gac                                      600
Phe Arg Thr Leu Gly Leu Leu Asp
        195                 200


<210> SEQ ID NO 4
<211> LENGTH: 200
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Met Asp Ser Leu Leu Met Asn Arg Arg Lys Phe Leu Tyr Gln Phe Lys
1               5                   10                  15

Asn Val Arg Trp Ala Lys Gly Arg Arg Glu Thr Tyr Leu Cys Tyr Val
            20                  25                  30

Val Lys Arg Arg Asp Ser Ala Thr Ser Phe Ser Leu Asp Phe Gly Tyr
        35                  40                  45

Leu Arg Asn Lys Asn Gly Cys His Val Glu Leu Leu Phe Leu Arg Tyr
    50                  55                  60

Ile Ser Asp Trp Asp Leu Asp Pro Gly Arg Cys Tyr Arg Val Thr Trp
65                  70                  75                  80

Phe Thr Ser Trp Ser Pro Cys Tyr Asp Cys Ala Arg His Val Ala Asp
                85                  90                  95

Phe Leu Arg Gly Asn Pro Tyr Leu Ser Leu Arg Ile Phe Thr Ala Arg
            100                 105                 110

Leu Tyr Phe Cys Glu Asp Arg Lys Ala Glu Pro Glu Gly Leu Arg Arg
        115                 120                 125

Leu His Arg Ala Gly Val Gln Ile Ala Ile Met Thr Phe Lys Asp Tyr
    130                 135                 140

Phe Tyr Cys Trp Asn Thr Phe Val Glu Asn His Glu Arg Thr Phe Lys
145                 150                 155                 160

Ala Trp Glu Gly Leu His Glu Asn Ser Val Arg Leu Ser Arg Gln Leu
                165                 170                 175

Arg Arg Ile Leu Leu Pro Leu Tyr Glu Val Asp Asp Leu Arg Asp Ala
            180                 185                 190

Phe Arg Thr Leu Gly Leu Leu Asp
        195                 200


<210> SEQ ID NO 5
<211> LENGTH: 4116
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Streptococcus pyogenes-derived Cas9 CDS
      optimized for eucaryotic expression.
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(4116)
```

-continued

```
<400> SEQUENCE: 5

atg gac aag aag tac tcc att ggg ctc gat atc ggc aca aac agc gtc      48
Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val
1               5                   10                  15

ggt tgg gcc gtc att acg gac gag tac aag gtg ccg agc aaa aaa ttc      96
Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe
            20                  25                  30

aaa gtt ctg ggc aat acc gat cgc cac agc ata aag aag aac ctc att     144
Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile
        35                  40                  45

ggc gcc ctc ctg ttc gac tcc ggg gag acg gcc gaa gcc acg cgg ctc     192
Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu
    50                  55                  60

aaa aga aca gca cgg cgc aga tat acc cgc aga aag aat cgg atc tgc     240
Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys
65                  70                  75                  80

tac ctg cag gag atc ttt agt aat gag atg gct aag gtg gat gac tct     288
Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser
                85                  90                  95

ttc ttc cat agg ctg gag gag tcc ttt ttg gtg gag gag gat aaa aag     336
Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys
            100                 105                 110

cac gag cgc cac cca atc ttt ggc aat atc gtg gac gag gtg gcg tac     384
His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr
        115                 120                 125

cat gaa aag tac cca acc ata tat cat ctg agg aag aag ctt gta gac     432
His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp
    130                 135                 140

agt act gat aag gct gac ttg cgg ttg atc tat ctc gcg ctg gcg cat     480
Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His
145                 150                 155                 160

atg atc aaa ttt cgg gga cac ttc ctc atc gag ggg gac ctg aac cca     528
Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro
                165                 170                 175

gac aac agc gat gtc gac aaa ctc ttt atc caa ctg gtt cag act tac     576
Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr
            180                 185                 190

aat cag ctt ttc gaa gag aac ccg atc aac gca tcc gga gtt gac gcc     624
Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala
        195                 200                 205

aaa gca atc ctg agc gct agg ctg tcc aaa tcc cgg cgg ctc gaa aac     672
Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn
    210                 215                 220

ctc atc gca cag ctc cct ggg gag aag aag aac ggc ctg ttt ggt aat     720
Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn
225                 230                 235                 240

ctt atc gcc ctg tca ctc ggg ctg acc ccc aac ttt aaa tct aac ttc     768
Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe
                245                 250                 255

gac ctg gcc gaa gat gcc aag ctt caa ctg agc aaa gac acc tac gat     816
Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp
            260                 265                 270

gat gat ctc gac aat ctg ctg gcc cag atc ggc gac cag tac gca gac     864
Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp
        275                 280                 285

ctt ttt ttg gcg gca aag aac ctg tca gac gcc att ctg ctg agt gat     912
```

-continued

```
Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp
    290                 295                 300

att ctg cga gtg aac acg gag atc acc aaa gct ccg ctg agc gct agt      960
Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser
305                 310                 315                 320

atg atc aag cgc tat gat gag cac cac caa gac ttg act ttg ctg aag     1008
Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys
                325                 330                 335

gcc ctt gtc aga cag caa ctg cct gag aag tac aag gaa att ttc ttc     1056
Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe
            340                 345                 350

gat cag tct aaa aat ggc tac gcc gga tac att gac ggc gga gca agc     1104
Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser
        355                 360                 365

cag gag gaa ttt tac aaa ttt att aag ccc atc ttg gaa aaa atg gac     1152
Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp
    370                 375                 380

ggc acc gag gag ctg ctg gta aag ctt aac aga gaa gat ctg ttg cgc     1200
Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg
385                 390                 395                 400

aaa cag cgc act ttc gac aat gga agc atc ccc cac cag att cac ctg     1248
Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu
                405                 410                 415

ggc gaa ctg cac gct atc ctc agg cgg caa gag gat ttc tac ccc ttt     1296
Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe
            420                 425                 430

ttg aaa gat aac agg gaa aag att gag aaa atc ctc aca ttt cgg ata     1344
Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile
        435                 440                 445

ccc tac tat gta ggc ccc ctc gcc cgg gga aat tcc aga ttc gcg tgg     1392
Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp
    450                 455                 460

atg act cgc aaa tca gaa gag acc atc act ccc tgg aac ttc gag gaa     1440
Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu
465                 470                 475                 480

gtc gtg gat aag ggg gcc tct gcc cag tcc ttc atc gaa agg atg act     1488
Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr
                485                 490                 495

aac ttt gat aaa aat ctg cct aac gaa aag gtg ctt cct aaa cac tct     1536
Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser
            500                 505                 510

ctg ctg tac gag tac ttc aca gtt tat aac gag ctc acc aag gtc aaa     1584
Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys
        515                 520                 525

tac gtc aca gaa ggg atg aga aag cca gca ttc ctg tct gga gag cag     1632
Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln
    530                 535                 540

aag aaa gct atc gtg gac ctc ctc ttc aag acg aac cgg aaa gtt acc     1680
Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr
545                 550                 555                 560

gtg aaa cag ctc aaa gaa gac tat ttc aaa aag att gaa tgt ttc gac     1728
Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp
                565                 570                 575

tct gtt gaa atc agc gga gtg gag gat cgc ttc aac gca tcc ctg gga     1776
Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly
            580                 585                 590

acg tat cac gat ctc ctg aaa atc att aaa gac aag gac ttc ctg gac     1824
```

-continued

```
Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp
        595                 600                 605

aat gag gag aac gag gac att ctt gag gac att gtc ctc acc ctt acg    1872
Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr
    610                 615                 620

ttg ttt gaa gat agg gag atg att gaa gaa cgc ttg aaa act tac gct    1920
Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala
625                 630                 635                 640

cat ctc ttc gac gac aaa gtc atg aaa cag ctc aag agg cgc cga tat    1968
His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr
                645                 650                 655

aca gga tgg ggg cgg ctg tca aga aaa ctg atc aat ggg atc cga gac    2016
Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp
            660                 665                 670

aag cag agt gga aag aca atc ctg gat ttt ctt aag tcc gat gga ttt    2064
Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe
        675                 680                 685

gcc aac cgg aac ttc atg cag ttg atc cat gat gac tct ctc acc ttt    2112
Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe
    690                 695                 700

aag gag gac atc cag aaa gca caa gtt tct ggc cag ggg gac agt ctt    2160
Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu
705                 710                 715                 720

cac gag cac atc gct aat ctt gca ggt agc cca gct atc aaa aag gga    2208
His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly
                725                 730                 735

ata ctg cag acc gtt aag gtc gtg gat gaa ctc gtc aaa gta atg gga    2256
Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly
            740                 745                 750

agg cat aag ccc gag aat atc gtt atc gag atg gcc cga gag aac caa    2304
Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln
        755                 760                 765

act acc cag aag gga cag aag aac agt agg gaa agg atg aag agg att    2352
Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile
    770                 775                 780

gaa gag ggt ata aaa gaa ctg ggg tcc caa atc ctt aag gaa cac cca    2400
Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro
785                 790                 795                 800

gtt gaa aac acc cag ctt cag aat gag aag ctc tac ctg tac tac ctg    2448
Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu
                805                 810                 815

cag aac ggc agg gac atg tac gtg gat cag gaa ctg gac atc aat cgg    2496
Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg
            820                 825                 830

ctc tcc gac tac gac gtg gat cat atc gtg ccc cag tct ttt ctc aaa    2544
Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys
        835                 840                 845

gat gat tct att gat aat aaa gtg ttg aca aga tcc gat aaa aat aga    2592
Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg
    850                 855                 860

ggg aag agt gat aac gtc ccc tca gaa gaa gtt gtc aag aaa atg aaa    2640
Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys
865                 870                 875                 880

aat tat tgg cgg cag ctg ctg aac gcc aaa ctg atc aca caa cgg aag    2688
Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys
                885                 890                 895

ttc gat aat ctg act aag gct gaa cga ggt ggc ctg tct gag ttg gat    2736
```

-continued

```
Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp
            900                 905                 910

aaa gcc ggc ttc atc aaa agg cag ctt gtt gag aca cgc cag atc acc    2784
Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr
        915                 920                 925

aag cac gtg gcc caa att ctc gat tca cgc atg aac acc aag tac gat    2832
Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp
    930                 935                 940

gaa aat gac aaa ctg att cga gag gtg aaa gtt att act ctg aag tct    2880
Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser
945                 950                 955                 960

aag ctg gtc tca gat ttc aga aag gac ttt cag ttt tat aag gtg aga    2928
Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg
                965                 970                 975

gag atc aac aat tac cac cat gcg cat gat gcc tac ctg aat gca gtg    2976
Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val
            980                 985                 990

gta ggc act gca ctt atc aaa aaa  tat ccc aag ctt gaa  tct gaa ttt  3024
Val Gly Thr Ala Leu Ile Lys Lys  Tyr Pro Lys Leu Glu  Ser Glu Phe
        995                 1000                1005

gtt tac  gga gac tat aaa gtg  tac gat gtt agg aaa  atg atc gca    3069
Val Tyr  Gly Asp Tyr Lys Val  Tyr Asp Val Arg Lys  Met Ile Ala
    1010                 1015                 1020

aag tct  gag cag gaa ata ggc  aag gcc acc gct aag  tac ttc ttt    3114
Lys Ser  Glu Gln Glu Ile Gly  Lys Ala Thr Ala Lys  Tyr Phe Phe
    1025                 1030                 1035

tac agc  aat att atg aat ttt  ttc aag acc gag att  aca ctg gcc    3159
Tyr Ser  Asn Ile Met Asn Phe  Phe Lys Thr Glu Ile  Thr Leu Ala
    1040                 1045                 1050

aat gga  gag att cgg aag cga  cca ctt atc gaa aca  aac gga gaa    3204
Asn Gly  Glu Ile Arg Lys Arg  Pro Leu Ile Glu Thr  Asn Gly Glu
    1055                 1060                 1065

aca gga  gaa atc gtg tgg gac  aag ggt agg gat ttc  gcg aca gtc    3249
Thr Gly  Glu Ile Val Trp Asp  Lys Gly Arg Asp Phe  Ala Thr Val
    1070                 1075                 1080

cgg aag  gtc ctg tcc atg ccg  cag gtg aac atc gtt  aaa aag acc    3294
Arg Lys  Val Leu Ser Met Pro  Gln Val Asn Ile Val  Lys Lys Thr
    1085                 1090                 1095

gaa gta  cag acc gga ggc ttc  tcc aag gaa agt atc  ctc ccg aaa    3339
Glu Val  Gln Thr Gly Gly Phe  Ser Lys Glu Ser Ile  Leu Pro Lys
    1100                 1105                 1110

agg aac  agc gac aag ctg atc  gca cgc aaa aaa gat  tgg gac ccc    3384
Arg Asn  Ser Asp Lys Leu Ile  Ala Arg Lys Lys Asp  Trp Asp Pro
    1115                 1120                 1125

aag aaa  tac ggc gga ttc gat  tct cct aca gtc gct  tac agt gta    3429
Lys Lys  Tyr Gly Gly Phe Asp  Ser Pro Thr Val Ala  Tyr Ser Val
    1130                 1135                 1140

ctg gtt  gtg gcc aaa gtg gag  aaa ggg aag tct aaa  aaa ctc aaa    3474
Leu Val  Val Ala Lys Val Glu  Lys Gly Lys Ser Lys  Lys Leu Lys
    1145                 1150                 1155

agc gtc  aag gaa ctg ctg ggc  atc aca atc atg gag  cga tca agc    3519
Ser Val  Lys Glu Leu Leu Gly  Ile Thr Ile Met Glu  Arg Ser Ser
    1160                 1165                 1170

ttc gaa  aaa aac ccc atc gac  ttt ctc gag gcg aaa  gga tat aaa    3564
Phe Glu  Lys Asn Pro Ile Asp  Phe Leu Glu Ala Lys  Gly Tyr Lys
    1175                 1180                 1185

gag gtc  aaa aaa gac ctc atc  att aag ctt ccc aag  tac tct ctc    3609
```

-continued

```
Glu Val  Lys Lys Asp Leu Ile  Ile Lys Leu Pro Lys  Tyr Ser Leu
    1190                1195                1200

ttt gag  ctt gaa aac ggc cgg  aaa cga atg ctc gct  agt gcg ggc     3654
Phe Glu  Leu Glu Asn Gly Arg  Lys Arg Met Leu Ala  Ser Ala Gly
    1205                1210                1215

gag ctg  cag aaa ggt aac gag  ctg gca ctg ccc tct  aaa tac gtt     3699
Glu Leu  Gln Lys Gly Asn Glu  Leu Ala Leu Pro Ser  Lys Tyr Val
    1220                1225                1230

aat ttc  ttg tat ctg gcc agc  cac tat gaa aag ctc  aaa ggg tct     3744
Asn Phe  Leu Tyr Leu Ala Ser  His Tyr Glu Lys Leu  Lys Gly Ser
    1235                1240                1245

ccc gaa  gat aat gag cag aag  cag ctg ttc gtg gaa  caa cac aaa     3789
Pro Glu  Asp Asn Glu Gln Lys  Gln Leu Phe Val Glu  Gln His Lys
    1250                1255                1260

cac tac  ctt gat gag atc atc  gag caa ata agc gaa  ttc tcc aaa     3834
His Tyr  Leu Asp Glu Ile Ile  Glu Gln Ile Ser Glu  Phe Ser Lys
    1265                1270                1275

aga gtg  atc ctc gcc gac gct  aac ctc gat aag gtg  ctt tct gct     3879
Arg Val  Ile Leu Ala Asp Ala  Asn Leu Asp Lys Val  Leu Ser Ala
    1280                1285                1290

tac aat  aag cac agg gat aag  ccc atc agg gag cag  gca gaa aac     3924
Tyr Asn  Lys His Arg Asp Lys  Pro Ile Arg Glu Gln  Ala Glu Asn
    1295                1300                1305

att atc  cac ttg ttt act ctg  acc aac ttg ggc gcg  cct gca gcc     3969
Ile Ile  His Leu Phe Thr Leu  Thr Asn Leu Gly Ala  Pro Ala Ala
    1310                1315                1320

ttc aag  tac ttc gac acc acc  ata gac aga aag cgg  tac acc tct     4014
Phe Lys  Tyr Phe Asp Thr Thr  Ile Asp Arg Lys Arg  Tyr Thr Ser
    1325                1330                1335

aca aag  gag gtc ctg gac gcc  aca ctg att cat cag  tca att acg     4059
Thr Lys  Glu Val Leu Asp Ala  Thr Leu Ile His Gln  Ser Ile Thr
    1340                1345                1350

ggg ctc  tat gaa aca aga atc  gac ctc tct cag ctc  ggt gga gac     4104
Gly Leu  Tyr Glu Thr Arg Ile  Asp Leu Ser Gln Leu  Gly Gly Asp
    1355                1360                1365

agc agg  gct gac                                                   4116
Ser Arg  Ala Asp
    1370


<210> SEQ ID NO 6
<211> LENGTH: 1372
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 6

Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val
1               5                   10                  15

Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe
            20                  25                  30

Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile
        35                  40                  45

Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu
    50                  55                  60

Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys
65                  70                  75                  80
```

-continued

```
Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser
                85                  90                  95

Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys
            100                 105                 110

His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr
        115                 120                 125

His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp
    130                 135                 140

Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His
145                 150                 155                 160

Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro
                165                 170                 175

Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr
            180                 185                 190

Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala
        195                 200                 205

Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn
    210                 215                 220

Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn
225                 230                 235                 240

Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe
                245                 250                 255

Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp
            260                 265                 270

Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp
        275                 280                 285

Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp
    290                 295                 300

Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser
305                 310                 315                 320

Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys
                325                 330                 335

Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe
            340                 345                 350

Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser
        355                 360                 365

Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp
    370                 375                 380

Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg
385                 390                 395                 400

Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu
                405                 410                 415

Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe
            420                 425                 430

Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile
        435                 440                 445

Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp
    450                 455                 460

Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu
465                 470                 475                 480

Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr
```

-continued

```
                485                 490                 495

Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser
            500                 505                 510

Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys
        515                 520                 525

Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln
    530                 535                 540

Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr
545                 550                 555                 560

Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp
                565                 570                 575

Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly
            580                 585                 590

Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp
        595                 600                 605

Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr
    610                 615                 620

Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala
625                 630                 635                 640

His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr
                645                 650                 655

Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp
            660                 665                 670

Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe
        675                 680                 685

Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe
    690                 695                 700

Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu
705                 710                 715                 720

His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly
                725                 730                 735

Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly
            740                 745                 750

Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln
        755                 760                 765

Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile
    770                 775                 780

Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro
785                 790                 795                 800

Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu
                805                 810                 815

Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg
            820                 825                 830

Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys
        835                 840                 845

Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg
    850                 855                 860

Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys
865                 870                 875                 880

Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys
                885                 890                 895
```

-continued

```
Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp
            900                 905                 910

Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr
        915                 920                 925

Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp
    930                 935                 940

Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser
945                 950                 955                 960

Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg
                965                 970                 975

Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val
            980                 985                 990

Val Gly Thr Ala Leu Ile Lys Lys  Tyr Pro Lys Leu Glu  Ser Glu Phe
        995                 1000                1005

Val Tyr  Gly Asp Tyr Lys Val  Tyr Asp Val Arg Lys  Met Ile Ala
    1010                1015                1020

Lys Ser  Glu Gln Glu Ile Gly  Lys Ala Thr Ala Lys  Tyr Phe Phe
    1025                1030                1035

Tyr Ser  Asn Ile Met Asn Phe  Phe Lys Thr Glu Ile  Thr Leu Ala
    1040                1045                1050

Asn Gly  Glu Ile Arg Lys Arg  Pro Leu Ile Glu Thr  Asn Gly Glu
    1055                1060                1065

Thr Gly  Glu Ile Val Trp Asp  Lys Gly Arg Asp Phe  Ala Thr Val
    1070                1075                1080

Arg Lys  Val Leu Ser Met Pro  Gln Val Asn Ile Val  Lys Lys Thr
    1085                1090                1095

Glu Val  Gln Thr Gly Gly Phe  Ser Lys Glu Ser Ile  Leu Pro Lys
    1100                1105                1110

Arg Asn  Ser Asp Lys Leu Ile  Ala Arg Lys Lys Asp  Trp Asp Pro
    1115                1120                1125

Lys Lys  Tyr Gly Gly Phe Asp  Ser Pro Thr Val Ala  Tyr Ser Val
    1130                1135                1140

Leu Val  Val Ala Lys Val Glu  Lys Gly Lys Ser Lys  Lys Leu Lys
    1145                1150                1155

Ser Val  Lys Glu Leu Leu Gly  Ile Thr Ile Met Glu  Arg Ser Ser
    1160                1165                1170

Phe Glu  Lys Asn Pro Ile Asp  Phe Leu Glu Ala Lys  Gly Tyr Lys
    1175                1180                1185

Glu Val  Lys Lys Asp Leu Ile  Ile Lys Leu Pro Lys  Tyr Ser Leu
    1190                1195                1200

Phe Glu  Leu Glu Asn Gly Arg  Lys Arg Met Leu Ala  Ser Ala Gly
    1205                1210                1215

Glu Leu  Gln Lys Gly Asn Glu  Leu Ala Leu Pro Ser  Lys Tyr Val
    1220                1225                1230

Asn Phe  Leu Tyr Leu Ala Ser  His Tyr Glu Lys Leu  Lys Gly Ser
    1235                1240                1245

Pro Glu  Asp Asn Glu Gln Lys  Gln Leu Phe Val Glu  Gln His Lys
    1250                1255                1260

His Tyr  Leu Asp Glu Ile Ile  Glu Gln Ile Ser Glu  Phe Ser Lys
    1265                1270                1275
```

-continued

Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala
1280 1285 1290

Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn
1295 1300 1305

Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala
1310 1315 1320

Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser
1325 1330 1335

Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr
1340 1345 1350

Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp
1355 1360 1365

Ser Arg Ala Asp
1370

<210> SEQ ID NO 7
<211> LENGTH: 83
<212> TYPE: DNA
<213> ORGANISM: Streptococcus pyogenes

<400> SEQUENCE: 7

gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60

ggcaccgagt cggtggtgct ttt 83

<210> SEQ ID NO 8
<211> LENGTH: 665
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 8

tttcaaaaat tcttactttt tttttggatg gacgcaaaga agtttaataa tcatattaca 60

tggcattacc accatataca tatccatata catatccata tctaatctta cttatatgtt 120

gtggaaatgt aaagagcccc attatcttag cctaaaaaaa ccttctcttt ggaactttca 180

gtaatacgct taactgctca ttgctatatt gaagtacgga ttagaagccg ccgagcgggt 240

gacagccctc cgaaggaaga ctctcctccg tgcgtcctcg tcttcaccgg tcgcgttcct 300

gaaacgcaga tgtgcctcgc gccgcactgc tccgaacaat aaagattcta caatactagc 360

ttttatggtt atgaagagga aaaattggca gtaacctggc cccacaaacc ttcaaatgaa 420

cgaatcaaat taacaaccat aggatgataa tgcgattagt tttttagcct tatttctggg 480

gtaattaatc agcgaagcga tgatttttga tctattaaca gatatataaa tgcaaaaact 540

gcataaccac tttaactaat actttcaaca ttttcggttt gtattacttc ttattcaaat 600

gtaataaaag tatcaacaaa aaattgttaa tatacctcta tactttaacg tcaaggagaa 660

aaaac 665

<210> SEQ ID NO 9
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Nuclear transition signal.
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(21)

-continued

<400> SEQUENCE: 9

```
ccc aag aag aag agg aag gtg                                          21
Pro Lys Lys Lys Arg Lys Val
1               5
```

<210> SEQ ID NO 10
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 10

```
Pro Lys Lys Lys Arg Lys Val
1               5
```

<210> SEQ ID NO 11
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: GS linker
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(15)

<400> SEQUENCE: 11

```
ggt gga gga ggt tct                                                  15
Gly Gly Gly Gly Ser
1               5
```

<210> SEQ ID NO 12
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 12

```
Gly Gly Gly Gly Ser
1               5
```

<210> SEQ ID NO 13
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Flag tag
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(66)

<400> SEQUENCE: 13

```
gac tat aag gac cac gac gga gac tac aag gat cat gat att gat tac      48
Asp Tyr Lys Asp His Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr
1               5                   10                  15

aaa gac gat gac gat aag                                              66
Lys Asp Asp Asp Asp Lys
            20
```

<210> SEQ ID NO 14
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

```
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 14

Asp Tyr Lys Asp His Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr
1               5                   10                  15

Lys Asp Asp Asp Asp Lys
            20


<210> SEQ ID NO 15
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Strep-tag
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(24)

<400> SEQUENCE: 15

tgg agc cac ccg cag ttc gaa aaa                                   24
Trp Ser His Pro Gln Phe Glu Lys
1               5


<210> SEQ ID NO 16
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 16

Trp Ser His Pro Gln Phe Glu Lys
1               5


<210> SEQ ID NO 17
<211> LENGTH: 171
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SH3 domain
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(171)

<400> SEQUENCE: 17

gca gag tat gtg cgg gcc ctc ttt gac ttt aat ggg aat gat gaa gaa       48
Ala Glu Tyr Val Arg Ala Leu Phe Asp Phe Asn Gly Asn Asp Glu Glu
1               5                   10                  15

gat ctt ccc ttt aag aaa gga gac atc ctg aga atc cgg gat aag cct       96
Asp Leu Pro Phe Lys Lys Gly Asp Ile Leu Arg Ile Arg Asp Lys Pro
            20                  25                  30

gaa gag cag tgg tgg aat gca gag gac agc gaa gga aag agg ggg atg      144
Glu Glu Gln Trp Trp Asn Ala Glu Asp Ser Glu Gly Lys Arg Gly Met
        35                  40                  45

att cct gtc cct tac gtg gag aag tat                                  171
Ile Pro Val Pro Tyr Val Glu Lys Tyr
    50                  55


<210> SEQ ID NO 18
<211> LENGTH: 57
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct
```

-continued

<400> SEQUENCE: 18

Ala Glu Tyr Val Arg Ala Leu Phe Asp Phe Asn Gly Asn Asp Glu Glu
1   5   10   15

Asp Leu Pro Phe Lys Lys Gly Asp Ile Leu Arg Ile Arg Asp Lys Pro
            20   25   30

Glu Glu Gln Trp Trp Asn Ala Glu Asp Ser Glu Gly Lys Arg Gly Met
        35   40   45

Ile Pro Val Pro Tyr Val Glu Lys Tyr
    50   55

<210> SEQ ID NO 19
<211> LENGTH: 188
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 19

gcgaatttct tatgatttat gatttttatt attaaataag ttataaaaaa aataagtgta 60

tacaaatttt aaagtgactc ttaggtttta aaacgaaaat tcttattctt gagtaactct 120

ttcctgtagg tcaggttgct ttctcaggta tagcatgagg tcgctcttat tgaccacacc 180

tctaccgg 188

<210> SEQ ID NO 20
<211> LENGTH: 417
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 20

ataccaggca tggagcttat ctggtccgtt cgagttttcg acgagtttgg agacattctt 60

tatagatgtc cttttttttt aatgatattc gttaaagaac aaaaagtcaa agcagtttaa 120

cctaacacct gttgttgatg ctacttgaaa caaggcttct aggcgaatac ttaaaaaggt 180

aatttcaata gcggtttata tatctgtttg cttttcaaga tattatgtaa acgcacgatg 240

tttttcgccc aggctttatt ttttttgttg ttgttgtctt ctcgaagaat tttctcgggc 300

agatctttgt cggaatgtaa aaaagcgcgt aattaaactt tctattatgc tgactaaaat 360

ggaagtgatc accaaaggct atttctgatt atataatcta gtcattactc gctcgag 417

<210> SEQ ID NO 21
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SH3-binding ligand
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(33)

<400> SEQUENCE: 21

cct cca cct gct ctg cca cct aag aga agg aga 33
Pro Pro Pro Ala Leu Pro Pro Lys Arg Arg Arg
1   5   10

<210> SEQ ID NO 22
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 22

Pro Pro Pro Ala Leu Pro Pro Lys Arg Arg Arg
1   5   10

<210> SEQ ID NO 23
<211> LENGTH: 269
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 23

tctttgaaaa gataatgtat gattatgctt tcactcatat ttatacagaa acttgatgtt   60

ttctttcgag tatatacaag gtgattacat gtacgtttga agtacaactc tagattttgt   120

agtgccctct tgggctagcg gtaaaggtgc gcattttttc acaccctaca atgttctgtt   180

caaaagattt tggtcaaacg ctgtagaagt gaaagttggt gcgcatgttt cggcgttcga   240

aacttctccg cagtgaaaga taaatgatc   269

<210> SEQ ID NO 24
<211> LENGTH: 14
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 24

tgttttttat gtct   14

<210> SEQ ID NO 25
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 25

gatacgttct ctatggagga   20

<210> SEQ ID NO 26
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 26

ttggagaaac ccaggtgcct   20

<210> SEQ ID NO 27
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 27

aacccaggtg cctggggtcc   20

<210> SEQ ID NO 28
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 28

ttggccaagt cattcaattt   20

-continued

<210> SEQ ID NO 29
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 29

ataacggaat ccaactgggc 20

<210> SEQ ID NO 30
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 30

gtcaattacg aagactgaac 20

<210> SEQ ID NO 31
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 31

gtcaatagga tcccctttt 19

<210> SEQ ID NO 32
<211> LENGTH: 10126
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Plasmid carrying dCas9-PmCDA1 fusion protein
and chimeric RNA targeting galK gene of E.coli
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (5561)..(5580)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 32

atcgccattc gccattcagg ctgcgcaact gttgggaagg gcgatcggtg cgggcctctt 60

cgctattacg ccagctggcg aaagggggat gtgctgcaag gcgattaagt tgggtaacgc 120

cagggttttc ccagtcacga cgttgtaaaa cgacggccag tgaattcgag ctcggtaccc 180

ggccgcaaac aacagataaa acgaaaggcc cagtctttcg actgagcctt tcgttttatt 240

tgatgcctgt caagtaacag caggactctt agtggtgtgg agtattttta cctgaatcat 300

aatggacaac tcgctccgtc gtttttcagc tcgcttcaaa gtcttctcaa gccatctatt 360

ctcattcaat tgattgtgcg acgattggat gaatattttc ctgcaacatt ggtagtgttc 420

acttaccatt acattcaacc caaccccgtt atctctgagg ttccacagcc caatttgatt 480

cctcgcattt ttctcgtaat agagtttgca agcccagatt ttcaaagtgt ggccgttccc 540

ccgcagctcc tggttatacc attctaagat cttttcagcg caatctgcac aaggactcca 600

ggatgagtac caatttatcg tgaattgtcc ggggttgtcg cgcaggtatt cttcgacttt 660

tctaatgcta aagatttcgg cgtgaatgcc acgttctgtc ccgctctgtg gtttattcac 720

agcatagccc caaaaacacg ctctacgttc accccgtcgt tttaattcaa agagaacgta 780

gcatctatgc gacacggatt ttttgttgtt gaaaaactgt ttcttaaacg tgtagatgtc 840

caacttctca tggattctca cgtactcagc gtcggtcatc ctagacttat cgtcatcgtc 900

tttgtaatca atatcatgat ccttgtagtc tccgtcgtgg tccttatagt ctccggactc 960

-continued

```
gagcctagac ttatcgtcat cgtctttgta atcaatatca tgatccttgt agtctccgtc   1020
gtggtcctta tagtctccgg aatacttctc cacgtaaggg acaggaatca tccccctctt   1080
tccttcgctg tcctctgcat tccaccactg ctcctcaggc ttatcccgga ttctcaggat   1140
gtctcctttc ttaaagggaa gatcctcttc atcattccca ttaaagtcaa agagggctcg   1200
cacatactca gcagaacctc cacctccaga acctcctcca ccgtcacctc ctagctgact   1260
caaatcaatg cgtgtttcat aaagaccagt gatggattga tggataagag tggcatctaa   1320
aacttctttt gtagacgtat atcgtttacg atcaattgtt gtatcaaaat atttaaaagc   1380
agcgggagct ccaagattcg tcaacgtaaa taaatgaata atattttctg cttgttcacg   1440
tattggtttg tctctatgtt tgttatatgc actaagaact ttatctaaat tggcatctgc   1500
taaaataaca cgcttagaaa attcactgat ttgctcaata atctcatcta aataatgctt   1560
atgctgctcc acaaacaatt gtttttgttc gttatcttct ggactaccct tcaacttttc   1620
ataatgacta gctaaatata aaaaattcac atatttgctt ggcagagcca gctcatttcc   1680
tttttgtaat tctccggcac tagccagcat ccgtttacga ccgttttcta actcaaaaag   1740
actatattta ggtagtttaa tgattaagtc ttttttaact tccttatatc ctttagcttc   1800
taaaaagtca atcggatttt tttcaaagga acttctttcc ataattgtga tccctagtaa   1860
ctctttaacg gattttaact tcttcgattt ccctttttcc accttagcaa ccactaggac   1920
tgaataagct accgttggac tatcaaaacc accatatttt tttggatccc agtctttttt   1980
acgagcaata agcttgtccg aatttctttt tggtaaaatt gactccttgg agaatccgcc   2040
tgtctgtact tctgttttct tgacaatatt gacttggggc atggacaata ctttgcgcac   2100
tgtggcaaaa tctcgccctt tatcccagac aatttctcca gtttccccat tagtttcgat   2160
tagagggcgt ttgcgaatct ctccatttgc aagtgtaatt tctgttttga agaagttcat   2220
gatattagag taaaagaaat attttgcggt tgctttgcct atttcttgct cagacttagc   2280
aatcatttta cgaacatcat aaactttata atcaccatag acaaactccg attcaagttt   2340
tggatatttc ttaatcaaag cagttccaac gacggcattt agatacgcat catgggcatg   2400
atggtaattg ttaatctcac gtactttata gaattggaaa tcttttcgga agtcagaaac   2460
taatttagat tttaaggtaa tcactttaac ctctcgaata agtttatcat tttcatcgta   2520
tttagtattc atgcgactat ccaaaatttg tgccacatgc ttagtgattt ggcgagtttc   2580
aaccaattgg cgtttgataa aaccagcttt atcaagttca ctcaaacctc cacgttcagc   2640
tttcgttaaa ttatcaaact tacgttgagt gattaacttg gcgtttagaa gttgtctcca   2700
atagttttc atctttttga ctacttcttc acttggaacg ttatccgatt taccacgatt   2760
tttatcagaa cgcgttaaga ccttattgtc tattgaatcg tctttaagga aactttgtgg   2820
aacaatggca tcgacatcat aatcacttaa acgattaata tctaattctt ggtccacata   2880
catgtctctt ccattttgga gataatagag atagagcttt tcattttgca attgagtatt   2940
ttcaacagga tgctctttaa gaatctgact tcctaattct ttgatacctt cttcgattcg   3000
tttcatacgc tctcgcgaat ttttctggcc cttttgagtt gtctgatttt cacgtgccat   3060
ttcaataacg atattttctg gcttatgccg ccccattact ttgaccaatt catcaacaac   3120
ttttacagtc tgtaaaatac ctttttttaat agcagggcta ccagctaaat ttgcaatatg   3180
ttcatgtaaa ctatcgcctt gtccagacac ttgtgctttt tgaatgtctt ctttaaatgt   3240
```

-continued

```
caaactatca tcatggatca gctgcataaa attgcgattg gcaaaaccat ctgatttcaa   3300
aaaatctaat attgttttgc cagattgctt atccctaata ccattaatca attttcgaga   3360
caaacgtccc caaccagtat aacggcgacg tttaagctgt ttcatcacct tatcatcaaa   3420
gaggtgagca tatgttttaa gtctttcctc aatcatctcc ctatcttcaa ataaggtcaa   3480
tgttaaaaca atatcctcta agatatcttc attttcttca ttatccaaaa aatctttatc   3540
tttaataatt tttagcaaat catggtaggt acctaatgaa gcattaaatc tatcttcaac   3600
tcctgaaatt tcaacactat caaaacattc tattttttg aaataatctt cttttaattg   3660
cttaacggtt acttttcgat ttgttttgaa gagtaaatca acaatggctt tcttctgttc   3720
acctgaaaga aatgctggtt ttcgcattcc ttcagtaaca tatttgacct ttgtcaattc   3780
gttataaacc gtaaaatact cataaagcaa actatgtttt ggtagtactt tttcatttgg   3840
aagattttta tcaaagtttg tcatgcgttc aataaatgat tgagctgaag cacctttatc   3900
gacaacttct tcaaaattcc atggggtaat tgtttcttca gacttccgag tcatccatgc   3960
aaaacgacta ttgccacgcg ccaatggacc aacataataa ggaattcgaa aagtcaagat   4020
tttttcaatc ttctcacgat tgtcttttaa aaatggataa aagtcttctt gtcttctcaa   4080
aatagcatgc agctcaccca agtgaatttg atggggaata gagccgttgt caaaggtccg   4140
ttgcttgcgc agcaaatctt cacgatttag tttcaccaat aattcctcag taccatccat   4200
tttttctaaa attggtttga taaatttata aaattcttct tggctagctc ccccatcaat   4260
ataacctgca tatccgtttt ttgattgatc aaaaaagatt tctttatact tttctggaag   4320
ttgttgtcga actaaagctt ttaaaagagt caagtcttga tgatgttcat cgtagcgttt   4380
aatcattgaa gctgataggg gagccttagt tatttcagta tttactctta ggatatctga   4440
aagtaaaata gcatctgata aattcttagc tgccaaaaac aaatcagcat attgatctcc   4500
aatttgcgcc aataaattat ctaaatcatc atcgtaagta tcttttgaaa gctgtaattt   4560
agcatcttct gccaaatcaa aatttgattt aaaattaggg gtcaaaccca atgacaaagc   4620
aatgagattc ccaaataagc catttttctt ctcaccgggg agctgagcaa tgagattttc   4680
taatcgtctt gatttactca atcgtgcaga aagaatcgct ttagcatcta ctccacttgc   4740
gttaataggg ttttcttcaa ataattgatt gtaggtttgt accaactgga taaatagttt   4800
gtccacatca ctattatcag gatttaaatc tccctcaatc aaaaaatgac cacgaaactt   4860
aatcatatgc gctaaggcca aatagattaa gcgcaaatcc gctttatcag tagaatctac   4920
caattttttt cgcagatgat agatagttgg atatttctca tgataagcaa cttcatctac   4980
tatatttcca aaaataggat gacgttcatg cttcttgtct tcttccacca aaaaagactc   5040
ttcaagtcga tgaaagaaac tatcatctac tttcgccatc tcatttgaaa aaatctcctg   5100
tagataacaa atacgattct tccgacgtgt ataccttcta cgagctgtcc gtttgagacg   5160
agtcgcttcc gctgtctctc cactgtcaaa taaaagagcc cctataagat ttttttgat    5220
actgtggcgg tctgtatttc ccagaacctt gaacttttta gacggaacct tatattcatc   5280
agtgatcacc gcccatccga cgctatttgt gccgatagct aagcctattg agtatttctt   5340
atccattttt gcctcctaaa atgggccctt taaattaaat ccataatgag tttgatgatt   5400
tcaataatag ttttaatgac ctccgaaatt agtttaatat gctttaattt ttctttttca   5460
aaatatctct tcaaaaaata ttacccaata cttaataata aatagattat aacacaaaat   5520
```

-continued

```
tcttttgaca agtagtttat tttgttataa ttctatagta nnnnnnnnnn nnnnnnnnnn   5580
gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt   5640
ggcaccgagt cggtgctttt tttgatactt ctattctact ctgactgcaa accaaaaaaa   5700
caagcgcttt caaaacgctt gttttatcat ttttagggaa attaatctct taatcctttt   5760
atcattctac atttaggcgc tgccatcttg ctaaacctac taagctccac aggatgattt   5820
cgtaatcccg caagaggccc ggcagtaccg gcataaccaa gcctatgcct acagcatcca   5880
gggtgacggt gccgaggatg acgatgagcg cattgttaga tttcatacac ggtgcctgac   5940
tgcgttagca atttaactgt gataaactac cgcattaaag cttatcgatg ataagctgtc   6000
aaacatgaga attacaactt atatcgtatg gggctgactt caggtgctac atttgaagag   6060
ataaattgca ctgaaatcta gtcggatcct cgctcactga ctcgctgcgc tcggtcgttc   6120
ggctgcggcg agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag   6180
gggataacgc aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa   6240
aggccgcgtt gctggcgttt ttccataggc tccgcccccc tgacgagcat cacaaaaatc   6300
gacgctcaag tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc   6360
ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg   6420
cctttctccc ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt   6480
cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga accccccgtt cagcccgacc   6540
gctgcgcctt atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc   6600
cactggcagc agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag   6660
agttcttgaa gtggtggcct aactacggct acactagaag gacagtattt ggtatctgcg   6720
ctctgctgaa gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa   6780
ccaccgctgg tagcggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag   6840
gatctcaaga agatcctttg atcttttcta cggggtctga cgctcagtgg aacgaaaact   6900
cacgttaagg gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa   6960
attaaaaatg aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt   7020
accaatgctt aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag   7080
ttgcctgact ccccgtcgtg tagataacta cgatacggga gggcttacca tctggcccca   7140
gtgctgcaat gataccgcga gaaccacgct caccggctcc agatttatca gcaataaacc   7200
agccagccgg aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt   7260
ctattaattg ttgccgggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcaacg   7320
ttgttgccat tgctgcaggc atcgtggtgt cacgctcgtc gtttggtatg gcttcattca   7380
gctccggttc ccaacgatca aggcgagtta catgatcccc catgttgtgc aaaaaagcgg   7440
ttagctcctt cggtcctccg atcgttgtca gaagtaagtt ggccgcagtg ttatcactca   7500
tggttatggc agcactgcat aattctctta ctgtcatgcc atccgtaaga tgcttttctg   7560
tgactggtga gtactcaacc aagtcattct gagaatagtg tatgcggcga ccgagttgct   7620
cttgcccggc gtcaacacgg gataataccg cgccacatag cagaacttta aaagtgctca   7680
tcattggaaa acgttcttcg gggcgaaaac tctcaaggat cttaccgctg ttgagatcca   7740
gttcgatgta acccactcgt gcacccaact gatcttcagc atcttttact ttcaccagcg   7800
```

-continued

```
tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata agggcgacac   7860
ggaaatgttg aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcagggtt   7920
attgtctcat gagcggatac atatttgaat gtatttagaa aaataaacaa ataggggttc   7980
cgcgcacatt tccccgaaaa gtgccacctg acgtcaatgc cgagcgaaag cgagccgaag   8040
ggtagcattt acgttagata accccctgat atgctccgac gctttatata gaaaagaaga   8100
ttcaactagg taaaatctta atataggttg agatgataag gtttataagg aatttgtttg   8160
ttctaatttt tcactcattt tgttctaatt tcttttaaca aatgttcttt ttttttttaga   8220
acagttatga tatagttaga atagtttaaa ataaggagtg agaaaaagat gaaagaaaga   8280
tatggaacag tctataaagg ctctcagagg ctcatagacg aagaaagtgg agaagtcata   8340
gaggtagaca agttataccg taaacaaacg tctggtaact tcgtaaaggc atatatagtg   8400
caattaataa gtatgttaga tatgattggc ggaaaaaaac ttaaaatcgt taactatatc   8460
ctagataatg tccacttaag taacaataca atgatagcta caacaagaga aatagcaaaa   8520
gctacaggaa caagtctaca aacagtaata acaacactta aaatcttaga agaaggaaat   8580
attataaaaa gaaaaactgg agtattaatg ttaaaccctg aactactaat gagaggcgac   8640
gaccaaaaac aaaaatacct cttactcgaa tttgggaact ttgagcaaga ggcaaatgaa   8700
atagattgac ctcccaataa caccacgtag ttattgggag gtcaatctat gaaatgcgat   8760
taagcttttt ctaattcaca taagcgtgca ggtttaaagt acataaaaaa tataatgaaa   8820
aaaagcatca ttatactaac gttataccaa cattatactc tcattatact aattgcttat   8880
tccaatttcc tattggttgg aaccaacagg cgttagtgtg ttgttgagtt ggtactttca   8940
tgggattaat cccatgaaac ccccaaccaa ctcgccaaag ctttggctaa cacacacgcc   9000
attccaacca atagttttct cggcataaag ccatgctctg acgcttaaat gcactaatgc   9060
cttaaaaaaa cattaaagtc taacacacta gacttattta cttcgtaatt aagtcgttaa   9120
accgtgtgct ctacgaccaa aagtataaaa cctttaagaa ctttcttttt tcttgtaaaa   9180
aaagaaacta gataaatctc tcatatcttt tattcaataa tcgcatcaga ttgcagtata   9240
aatttaacga tcactcatca tgttcatatt tatcagagct cgtgctataa ttatactaat   9300
tttataagga ggaaaaaata aagagggtta taatgaacga gaaaaatata aaacacagtc   9360
aaaactttat tacttcaaaa cataatatag ataaaataat gacaaatata agattaaatg   9420
aacatgataa tatctttgaa atcggctcag gaaaagggca ttttaccctt gaattagtac   9480
agaggtgtaa tttcgtaact gccattgaaa tagaccataa attatgcaaa actacagaaa   9540
ataaacttgt tgatcacgat aatttccaag ttttaaacaa ggatatattg cagtttaaat   9600
ttcctaaaaa ccaatcctat aaaatatttg gtaatatacc ttataacata agtacggata   9660
taatacgcaa aattgttttt gatagtatag ctgatgagat ttatttaatc gtggaatacg   9720
ggtttgctaa aagattatta aatacaaaac gctcattggc attatttta atggcagaag   9780
ttgatatttc tatattaagt atggttccaa gagaatattt tcatcctaaa cctaaagtga   9840
atagctcact tatcagatta aatagaaaaa aatcaagaat atcacacaaa gataaacaga   9900
agtataatta tttcgttatg aaatgggtta acaaagaata caagaaaata tttacaaaaa   9960
atcaatttaa caattcctta aaacatgcag gaattgacga tttaaacaat attagctttg  10020
aacaattctt atctcttttc aatagctata aattatttaa taagtaagtt aagggatgca  10080
```

-continued

```
taaactgcat cccttaactt gtttttcgtg tacctatttt ttgtga               10126


<210> SEQ ID NO 33
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 33

tcaatgggct aactacgttc                                               20


<210> SEQ ID NO 34
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 34

ggtccataaa ctgagacagc                                               20


<210> SEQ ID NO 35
<211> LENGTH: 223
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 35

gagttataca cagggctggg atctattctt tttatctttt tttattcttt ctttattcta     60

taaattataa ccacttgaat ataaacaaaa aaaacacaca aaggtctagc ggaatttaca    120

gagggtctag cagaatttac aagttttcca gcaaaggtct agcagaattt acagataccc    180

acaactcaaa ggaaaaggac tagtaattat cattgactag ccc                      223


<210> SEQ ID NO 36
<211> LENGTH: 951
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 36

atgtctgaat tagttgtttt caaagcaaat gaactagcga ttagtcgcta tgacttaacg     60

gagcatgaaa ccaagctaat tttatgctgt gtggcactac tcaaccccac gattgaaaac    120

cctacaatga aagaacggac ggtatcgttc acttataacc aatacgttca gatgatgaac    180

atcagtaggg aaaatgctta tggtgtatta gctaaagcaa ccagagagct gatgacgaga    240

actgtggaaa tcaggaatcc tttggttaaa ggctttgaga ttttccagtg gacaaactat    300

gccaagttct caagcgaaaa attagaatta gtttttagtg aagagatatt gccttatctt    360

ttccagttaa aaaaattcat aaaatataat ctggaacatg ttaagtcttt tgaaaacaaa    420

tactctatga ggatttatga gtggttatta aaagaactaa cacaaaagaa aactcacaag    480

gcaaatatag agattagcct tgatgaattt aagttcatgt taatgcttga aaataactac    540

catgagttta aaaggcttaa ccaatgggtt ttgaaaccaa taagtaaaga tttaaacact    600

tacagcaata tgaaattggt ggttgataag cgaggccgcc cgactgatac gttgattttc    660

caagttgaac tagatagaca aatggatctc gtaaccgaac ttgagaacaa ccagataaaa    720

atgaatggtg acaaaatacc aacaaccatt acatcagatt cctacctaca taacggacta    780

agaaaaacac tacacgatgc tttaactgca aaaattcagc tcaccagttt tgaggcaaaa    840

tttttgagtg acatgcaaag taagcatgat ctcaatggtt cgttctcatg gctcacgcaa    900
```

-continued

aaacaacgaa ccacactaga gaacatactg gctaaatacg gaaggatctg a 951

<210> SEQ ID NO 37
<211> LENGTH: 714
<212> TYPE: DNA
<213> ORGANISM: Bacteriophage lambda

<400> SEQUENCE: 37

tcagccaaac gtctcttcag gccactgact agcgataact ttccccacaa cggaacaact 60

ctcattgcat gggatcattg ggtactgtgg gtttagtggt tgtaaaaaca cctgaccgct 120

atccctgatc agtttcttga aggtaaactc atcaccccca agtctggcta tgcagaaatc 180

acctggctca acagcctgct cagggtcaac gagaattaac attccgtcag gaaagcttgg 240

cttggagcct gttggtgcgg tcatggaatt accttcaacc tcaagccaga atgcagaatc 300

actggctttt ttggttgtgc ttacccatct ctccgcatca cctttggtaa aggttctaag 360

cttaggtgag aacatccctg cctgaacatg agaaaaaaca gggtactcat actcacttct 420

aagtgacggc tgcatactaa ccgcttcata catctcgtag atttctctgg cgattgaagg 480

gctaaattct tcaacgctaa ctttgagaat ttttgtaagc aatgcggcgt tataagcatt 540

taatgcattg atgccattaa ataaagcacc aacgcctgac tgccccatcc ccatcttgtc 600

tgcgacagat tcctgggata agccaagttc atttttcttt ttttcataaa ttgctttaag 660

gcgacgtgcg tcctcaagct gctcttgtgt taatggtttc ttttttgtgc tcat 714

<210> SEQ ID NO 38
<211> LENGTH: 5097
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: dCas9-PmCDA1

<400> SEQUENCE: 38

atggataaga aatactcaat aggcttagct atcggcacaa atagcgtcgg atgggcggtg 60

atcactgatg aatataaggt tccgtctaaa aagttcaagg ttctgggaaa tacagaccgc 120

cacagtatca aaaaaaatct tataggggct cttttatttg acagtggaga gacagcggaa 180

gcgactcgtc tcaaacggac agctcgtaga aggtatacac gtcggaagaa tcgtatttgt 240

tatctacagg agattttttc aaatgagatg gcgaaagtag atgatagttt ctttcatcga 300

cttgaagagt cttttttggt ggaagaagac aagaagcatg aacgtcatcc tatttttgga 360

aatatagtag atgaagttgc ttatcatgag aaatatccaa ctatctatca tctgcgaaaa 420

aaattggtag attctactga taaagcggat ttgcgcttaa tctatttggc cttagcgcat 480

atgattaagt ttcgtggtca tttttttgatt gagggagatt taaatcctga taatagtgat 540

gtggacaaac tatttatcca gttggtacaa acctacaatc aattatttga agaaaaccct 600

attaacgcaa gtggagtaga tgctaaagcg attctttctg cacgattgag taaatcaaga 660

cgattagaaa atctcattgc tcagctcccc ggtgagaaga aaaatggctt atttgggaat 720

ctcattgctt tgtcattggg tttgacccct aattttaaat caaattttga tttggcagaa 780

gatgctaaat tacagctttc aaaagatact tacgatgatg atttagataa tttattggcg 840

caaattggag atcaatatgc tgatttgttt ttggcagcta agaatttatc agatgctatt 900

ttactttcag atatcctaag agtaaatact gaaataacta aggctcccct atcagcttca 960

-continued

```
atgattaaac gctacgatga acatcatcaa gacttgactc ttttaaaagc tttagttcga   1020
caacaacttc cagaaaagta taaagaaatc ttttttgatc aatcaaaaaa cggatatgca   1080
ggttatattg atgggggagc tagccaagaa gaattttata aatttatcaa accaatttta   1140
gaaaaaatgg atggtactga ggaattattg gtgaaactaa atcgtgaaga tttgctgcgc   1200
aagcaacgga cctttgacaa cggctctatt ccccatcaaa ttcacttggg tgagctgcat   1260
gctattttga gaagacaaga agacttttat ccatttttaa aagacaatcg tgagaagatt   1320
gaaaaaatct tgacttttcg aattccttat tatgttggtc cattggcgcg tggcaatagt   1380
cgttttgcat ggatgactcg gaagtctgaa gaaacaatta ccccatggaa ttttgaagaa   1440
gttgtcgata aaggtgcttc agctcaatca tttattgaac gcatgacaaa ctttgataaa   1500
aatcttccaa atgaaaaagt actaccaaaa catagtttgc tttatgagta ttttacggtt   1560
tataacgaat tgacaaaggt caaatatgtt actgaaggaa tgcgaaaacc agcatttctt   1620
tcaggtgaac agaagaaagc cattgttgat ttactcttca aaacaaatcg aaaagtaacc   1680
gttaagcaat taaaagaaga ttatttcaaa aaaatagaat gttttgatag tgttgaaatt   1740
tcaggagttg aagatagatt taatgcttca ttaggtacct accatgattt gctaaaaatt   1800
attaaagata aagatttttt ggataatgaa gaaaatgaag atatcttaga ggatattgtt   1860
ttaacattga ccttatttga agatagggag atgattgagg aaagacttaa aacatatgct   1920
cacctctttg atgataaggt gatgaaacag cttaaacgtc gccgttatac tggttgggga   1980
cgtttgtctc gaaaattgat taatggtatt agggataagc aatctggcaa aacaatatta   2040
gatttttga aatcagatgg ttttgccaat cgcaatttta tgcagctgat ccatgatgat   2100
agtttgacat ttaaagaaga cattcaaaaa gcacaagtgt ctggacaagg cgatagttta   2160
catgaacata ttgcaaattt agctggtagc cctgctatta aaaaaggtat tttacagact   2220
gtaaaagttg ttgatgaatt ggtcaaagta atggggcggc ataagccaga aaatatcgtt   2280
attgaaatgg cacgtgaaaa tcagacaact caaaagggcc agaaaaattc gcgagagcgt   2340
atgaaacgaa tcgaagaagg tatcaaagaa ttaggaagtc agattcttaa agagcatcct   2400
gttgaaaata ctcaattgca aaatgaaaag ctctatctct attatctcca aaatggaaga   2460
gacatgtatg tggaccaaga attagatatt aatcgtttaa gtgattatga tgtcgatgcc   2520
attgttccac aaagtttcct taaagacgat tcaatagaca ataaggtctt aacgcgttct   2580
gataaaaatc gtggtaaatc ggataacgtt ccaagtgaag aagtagtcaa aaagatgaaa   2640
aactattgga gacaacttct aaacgccaag ttaatcactc aacgtaagtt tgataattta   2700
acgaaagctg aacgtggagg tttgagtgaa cttgataaag ctggttttat caaacgccaa   2760
ttggttgaaa ctcgccaaat cactaagcat gtggcacaaa ttttggatag tcgcatgaat   2820
actaaatacg atgaaaatga taaacttatt cgagaggtta aagtgattac cttaaaatct   2880
aaattagttt ctgacttccg aaaagatttc caattctata aagtacgtga gattaacaat   2940
taccatcatg cccatgatgc gtatctaaat gccgtcgttg gaactgcttt gattaagaaa   3000
tatccaaaac ttgaatcgga gtttgtctat ggtgattata aagtttatga tgttcgtaaa   3060
atgattgcta agtctgagca agaaataggc aaagcaaccg caaaatattt cttttactct   3120
aatatcatga acttcttcaa aacagaaatt acacttgcaa atggagagat tcgcaaacgc   3180
cctctaatcg aaactaatgg ggaaactgga gaaattgtct gggataaagg gcgagatttt   3240
```

-continued

```
gccacagtgc gcaaagtatt gtccatgccc caagtcaata ttgtcaagaa aacagaagta   3300

cagacaggcg gattctccaa ggagtcaatt ttaccaaaaa gaaattcgga caagcttatt   3360

gctcgtaaaa aagactggga tccaaaaaaa tatggtggtt ttgatagtcc aacggtagct   3420

tattcagtcc tagtggttgc taaggtggaa aaagggaaat cgaagaagtt aaaatccgtt   3480

aaagagttac tagggatcac aattatggaa agaagttcct ttgaaaaaaa tccgattgac   3540

tttttagaag ctaaaggata taaggaagtt aaaaaagact taatcattaa actacctaaa   3600

tatagtcttt ttgagttaga aaacggtcgt aaacggatgc tggctagtgc cggagaatta   3660

caaaaaggaa atgagctggc tctgccaagc aaatatgtga atttttata tttagctagt   3720

cattatgaaa agttgaaggg tagtccagaa gataacgaac aaaaacaatt gtttgtggag   3780

cagcataagc attatttaga tgagattatt gagcaaatca gtgaattttc taagcgtgtt   3840

attttagcag atgccaattt agataaagtt cttagtgcat ataacaaaca tagagacaaa   3900

ccaatacgtg aacaagcaga aaatattatt catttattta cgttgacgaa tcttggagct   3960

cccgctgctt ttaaatattt tgatacaaca attgatcgta aacgatatac gtctacaaaa   4020

gaagttttag atgccactct tatccatcaa tccatcactg gtctttatga aacacgcatt   4080

gatttgagtc agctaggagg tgacggtgga ggaggttctg gaggtggagg ttctgctgag   4140

tatgtgcgag ccctctttga ctttaatggg aatgatgaag aggatcttcc ctttaagaaa   4200

ggagacatcc tgagaatccg ggataagcct gaggagcagt ggtggaatgc agaggacagc   4260

gaaggaaaga gggggatgat tcctgtccct tacgtggaga agtattccgg agactataag   4320

gaccacgacg gagactacaa ggatcatgat attgattaca aagacgatga cgataagtct   4380

aggctcgagt ccggagacta taaggaccac gacggagact acaaggatca tgatattgat   4440

tacaaagacg atgacgataa gtctaggatg accgacgctg agtacgtgag aatccatgag   4500

aagttggaca tctacacgtt taagaaacag tttttcaaca acaaaaaatc cgtgtcgcat   4560

agatgctacg ttctctttga attaaaacga cggggtgaac gtagagcgtg tttttggggc   4620

tatgctgtga ataaaccaca gagcgggaca gaacgtggca ttcacgccga aatctttagc   4680

attagaaaag tcgaagaata cctgcgcgac aaccccggac aattcacgat aaattggtac   4740

tcatcctgga gtccttgtgc agattgcgct gaaaagatct tagaatggta taaccaggag   4800

ctgcggggga acggccacac tttgaaaatc tgggcttgca aactctatta cgagaaaaat   4860

gcgaggaatc aaattgggct gtggaacctc agagataacg ggttgggtt gaatgtaatg   4920

gtaagtgaac actaccaatg ttgcaggaaa atattcatcc aatcgtcgca caatcaattg   4980

aatgagaata gatggcttga gaagactttg aagcgagctg aaaaacgacg gagcgagttg   5040

tccattatga ttcaggtaaa aatactccac accactaaga gtcctgctgt tacttga      5097
```

<210> SEQ ID NO 39
<211> LENGTH: 105
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 39

```
acgttaaatc tatcaccgca agggataaat atctaacacc gtgcgtgttg actattttac     60

ctctggcggt gataatggtt gcagggccca ttttaggagg caaaa                    105
```

<210> SEQ ID NO 40

-continued

<211> LENGTH: 247
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gRNA

<400> SEQUENCE: 40

ggtttagcaa gatggcagcg cctaaatgta gaatgataaa aggattaaga gattaatttc 60

cctaaaaatg ataaaacaag cgttttgaaa gcgcttgttt ttttggtttg cagtcagagt 120

agaatagaag tatcaaaaaa agcaccgact cggtgccact ttttcaagtt gataacggac 180

tagccttatt ttaacttgct atttctagct ctaaaactga gaccatcccg ggtctctact 240

gcagaat 247

<210> SEQ ID NO 41
<211> LENGTH: 64
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 41

tatcaccgcc agtggtattt atgtcaacac cgccagagat aatttatcac cgcagatggt 60

tatc 64

<210> SEQ ID NO 42
<211> LENGTH: 10867
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Plasmid

<400> SEQUENCE: 42

gtcggaactg actaaagtag tgagttatac acagggctgg gatctattct ttttatcttt 60

ttttattctt tctttattct ataaattata accacttgaa tataaacaaa aaaaacacac 120

aaaggtctag cggaatttac agagggtcta gcagaattta caagttttcc agcaaaggtc 180

tagcagaatt tacagatacc cacaactcaa aggaaaagga ctagtaatta tcattgacta 240

gcccatctca attggtatag tgattaaaat cacctagacc aattgagatg tatgtctgaa 300

ttagttgttt tcaaagcaaa tgaactagcg attagtcgct atgacttaac ggagcatgaa 360

accaagctaa ttttatgctg tgtggcacta ctcaacccca cgattgaaaa ccctacaatg 420

aaagaacgga cggtatcgtt cacttataac caatacgttc agatgatgaa catcagtagg 480

gaaaatgctt atggtgtatt agctaaagca accagagagc tgatgacgag aactgtggaa 540

atcaggaatc ctttggttaa aggctttgag attttccagt ggacaaacta tgccaagttc 600

tcaagcgaaa aattagaatt agtttttagt gaagagatat tgccttatct tttccagtta 660

aaaaaattca taaaatataa tctggaacat gttaagtctt ttgaaaacaa atactctatg 720

aggatttatg agtggttatt aaaagaacta acacaaaaga aaactcacaa ggcaaatata 780

gagattagcc ttgatgaatt taagttcatg ttaatgcttg aaaataacta ccatgagttt 840

aaaaggctta accaatgggt tttgaaacca ataagtaaag atttaaacac ttacagcaat 900

atgaaattgg tggttgataa gcgaggccgc ccgactgata cgttgatttt ccaagttgaa 960

ctagatagac aaatggatct cgtaaccgaa cttgagaaca accagataaa aatgaatggt 1020

gacaaaatac caacaaccat tacatcagat tcctacctac ataacggact aagaaaaaca 1080

-continued

ctacacgatg ctttaactgc aaaaattcag ctcaccagtt ttgaggcaaa atttttgagt 1140

gacatgcaaa gtaagcatga tctcaatggt tcgttctcat ggctcacgca aaaacaacga 1200

accacactag agaacatact ggctaaatac ggaaggatct gaggttctta tggctcttgt 1260

atctatcagt gaagcatcaa gactaacaaa caaaagtaga acaactgttc accgttacat 1320

atcaaaggga aaactgtcca tatgcacaga gataatctca tgaccaaaac cggtagctag 1380

aggggccgca ttaggcaccc caggctttac actttatgct tccggctcgt ataatgtgtg 1440

gattttgagt taggatccgg cgagattttc aggagctaag gaagctaaaa tggagaaaaa 1500

aatcactgga tataccaccg ttgatatatc ccaatggcat cgtaaagaac attttgaggc 1560

atttcagtca gttgctcaat gtacctataa ccagaccgtt cagctggata ttacggcctt 1620

tttaaagacc gtaaagaaaa ataagcacaa gttttatccg gcctttattc acattcttgc 1680

ccgcctgatg aatgctcatc cggaattccg tatggcaatg aaagacggtg agctggtgat 1740

atgggatagt gttcaccctt gttacaccgt tttccatgag caaactgaaa cgttttcatc 1800

gctctggagt gaataccacg acgatttccg gcagtttcta cacatatatt cgcaagatgt 1860

ggcgtgttac ggtgaaaacc tggcctattt ccctaaaggg tttattgaga atatgttttt 1920

cgtctcagcc aatccctggg tgagtttcac cagttttgat ttaaacgtgg ccaatatgga 1980

caacttcttc gcccccgttt tcaccatggg caaatattat acgcaaggcg acaaggtgct 2040

gatgccgctg gcgattcagg ttcatcatgc cgtctgtgat ggcttccatg tcggcagaat 2100

gcttaatgaa ttacaacagt actgcgatga gtggcagggc ggggcgtaaa cgcgtggatc 2160

cggcttacta aaagccagat aacagtatgc gtatttgcgc gctgattttt gcggtctaga 2220

ggtttagcaa gatggcagcg cctaaatgta gaatgataaa aggattaaga gattaatttc 2280

cctaaaaatg ataaaacaag cgttttgaaa gcgcttgttt ttttggtttg cagtcagagt 2340

agaatagaag tatcaaaaaa agcaccgact cggtgccact ttttcaagtt gataacggac 2400

tagccttatt ttaacttgct atttctagct ctaaaactga gaccatcccg ggtctctact 2460

gcagaattat caccgccagt ggtatttatg tcaacaccgc cagagataat ttatcaccgc 2520

agatggttat cgatgaagat tcttgctcaa ttgttatcag ctatgcgccg accagaacac 2580

cttgccgatc agccaaacgt ctcttcaggc cactgactag cgataacttt ccccacaacg 2640

gaacaactct cattgcatgg gatcattggg tactgtgggt ttagtggttg taaaaacacc 2700

tgaccgctat ccctgatcag tttcttgaag gtaaactcat cacccccaag tctggctatg 2760

cagaaatcac ctggctcaac agcctgctca gggtcaacga gaattaacat tccgtcagga 2820

aagcttggct tggagcctgt tggtgcggtc atggaattac cttcaacctc aagccagaat 2880

gcagaatcac tggctttttt ggttgtgctt acccatctct ccgcatcacc tttggtaaag 2940

gttctaagct taggtgagaa catccctgcc tgaacatgag aaaaaacagg gtactcatac 3000

tcacttctaa gtgacggctg catactaacc gcttcataca tctcgtagat ttctctggcg 3060

attgaagggc taaattcttc aacgctaact ttgagaattt ttgtaagcaa tgcggcgtta 3120

taagcattta atgcattgat gccattaaat aaagcaccaa cgcctgactg ccccatcccc 3180

atcttgtctg cgacagattc ctgggataag ccaagttcat ttttcttttt ttcataaatt 3240

gctttaaggc gacgtgcgtc ctcaagctgc tcttgtgtta atggtttctt ttttgtgctc 3300

atacgttaaa tctatcaccg caagggataa atatctaaca ccgtgcgtgt tgactatttt 3360

-continued

```
acctctggcg gtgataatgg ttgcagggcc cattttagga ggcaaaaatg gataagaaat   3420
actcaatagg cttagctatc ggcacaaata gcgtcggatg ggcggtgatc actgatgaat   3480
ataaggttcc gtctaaaaag ttcaaggttc tgggaaatac agaccgccac agtatcaaaa   3540
aaaatcttat aggggctctt ttatttgaca gtggagagac agcggaagcg actcgtctca   3600
aacggacagc tcgtagaagg tatacacgtc ggaagaatcg tatttgttat ctacaggaga   3660
tttttcaaa tgagatggcg aaagtagatg atagtttctt tcatcgactt gaagagtctt    3720
ttttggtgga agaagacaag aagcatgaac gtcatcctat ttttggaaat atagtagatg   3780
aagttgctta tcatgagaaa tatccaacta tctatcatct gcgaaaaaaa ttggtagatt   3840
ctactgataa agcggatttg cgcttaatct atttggcctt agcgcatatg attaagtttc   3900
gtggtcattt tttgattgag ggagatttaa atcctgataa tagtgatgtg gacaaactat   3960
ttatccagtt ggtacaaacc tacaatcaat tatttgaaga aaaccctatt aacgcaagtg   4020
gagtagatgc taaagcgatt ctttctgcac gattgagtaa atcaagacga ttagaaaatc   4080
tcattgctca gctccccggt gagaagaaaa atggcttatt tgggaatctc attgctttgt   4140
cattgggttt gacccctaat tttaaatcaa attttgattt ggcagaagat gctaaattac   4200
agctttcaaa agatacttac gatgatgatt tagataattt attggcgcaa attggagatc   4260
aaatatgctga tttgtttttg gcagctaaga atttatcaga tgctatttta ctttcagata  4320
tcctaagagt aaatactgaa ataactaagg ctcccctatc agcttcaatg attaaacgct   4380
acgatgaaca tcatcaagac ttgactcttt taaaagcttt agttcgacaa caacttccag   4440
aaaagtataa agaaatcttt tttgatcaat caaaaaacgg atatgcaggt tatattgatg   4500
ggggagctag ccaagaagaa ttttataaat ttatcaaacc aattttagaa aaaatggatg   4560
gtactgagga attattggtg aaactaaatc gtgaagattt gctgcgcaag caacggacct   4620
ttgacaacgg ctctattccc catcaaattc acttgggtga gctgcatgct attttgagaa   4680
gacaagaaga cttttatcca tttttaaaag acaatcgtga gaagattgaa aaaatcttga   4740
cttttcgaat tccttattat gttggtccat tggcgcgtgg caatagtcgt tttgcatgga   4800
tgactcggaa gtctgaagaa acaattaccc catggaattt tgaagaagtt gtcgataaag   4860
gtgcttcagc tcaatcattt attgaacgca tgacaaactt tgataaaaat cttccaaatg   4920
aaaaagtact accaaaacat agtttgcttt atgagtattt tacggtttat aacgaattga   4980
caaaggtcaa atatgttact gaaggaatgc gaaaaccagc atttctttca ggtgaacaga   5040
agaaagccat tgttgattta ctcttcaaaa caaatcgaaa agtaaccgtt aagcaattaa   5100
aagaagatta tttcaaaaaa atagaatgtt ttgatagtgt tgaaatttca ggagttgaag   5160
atagatttaa tgcttcatta ggtacctacc atgatttgct aaaaattatt aaagataaag   5220
attttttgga taatgaagaa aatgaagata tcttagagga tattgtttta acattgacct   5280
tatttgaaga tagggagatg attgaggaaa gacttaaaac atatgctcac ctctttgatg   5340
ataaggtgat gaaacagctt aaacgtcgcc gttatactgg ttggggacgt ttgtctcgaa   5400
aattgattaa tggtattagg gataagcaat ctggcaaaac aatattagat tttttgaaat   5460
cagatggttt tgccaatcgc aattttatgc agctgatcca tgatgatagt ttgacattta   5520
aagaagacat tcaaaaagca caagtgtctg gacaaggcga tagtttacat gaacatattg   5580
caaatttagc tggtagccct gctattaaaa aaggtatttt acagactgta aaagttgttg   5640
```

-continued

```
atgaattggt caaagtaatg gggcggcata agccagaaaa tatcgttatt gaaatggcac   5700
gtgaaaatca gacaactcaa aagggccaga aaaattcgcg agagcgtatg aaacgaatcg   5760
aagaaggtat caaagaatta ggaagtcaga ttcttaaaga gcatcctgtt gaaaatactc   5820
aattgcaaaa tgaaaagctc tatctctatt atctccaaaa tggaagagac atgtatgtgg   5880
accaagaatt agatattaat cgtttaagtg attatgatgt cgatgccatt gttccacaaa   5940
gtttccttaa agacgattca atagacaata aggtcttaac gcgttctgat aaaaatcgtg   6000
gtaaatcgga taacgttcca agtgaagaag tagtcaaaaa gatgaaaaac tattggagac   6060
aacttctaaa cgccaagtta atcactcaac gtaagtttga taatttaacg aaagctgaac   6120
gtggaggttt gagtgaactt gataaagctg gttttatcaa acgccaattg gttgaaactc   6180
gccaaatcac taagcatgtg gcacaaattt tggatagtcg catgaatact aaatacgatg   6240
aaaatgataa acttattcga gaggttaaag tgattacctt aaaatctaaa ttagtttctg   6300
acttccgaaa agatttccaa ttctataaag tacgtgagat taacaattac catcatgccc   6360
atgatgcgta tctaaatgcc gtcgttggaa ctgctttgat taagaaatat ccaaaacttg   6420
aatcggagtt tgtctatggt gattataaag tttatgatgt tcgtaaaatg attgctaagt   6480
ctgagcaaga aataggcaaa gcaaccgcaa aatatttctt ttactctaat atcatgaact   6540
tcttcaaaac agaaattaca cttgcaaatg gagagattcg caaacgccct ctaatcgaaa   6600
ctaatgggga aactggagaa attgtctggg ataaagggcg agattttgcc acagtgcgca   6660
aagtattgtc catgccccaa gtcaatattg tcaagaaaac agaagtacag acaggcggat   6720
tctccaagga gtcaatttta ccaaaaagaa attcggacaa gcttattgct cgtaaaaaag   6780
actgggatcc aaaaaaatat ggtggttttg atagtccaac ggtagcttat tcagtcctag   6840
tggttgctaa ggtggaaaaa gggaaatcga agaagttaaa atccgttaaa gagttactag   6900
ggatcacaat tatggaaaga agttcctttg aaaaaaatcc gattgacttt ttagaagcta   6960
aaggatataa ggaagttaaa aaagacttaa tcattaaact acctaaatat agtctttttg   7020
agttagaaaa cggtcgtaaa cggatgctgg ctagtgccgg agaattacaa aaaggaaatg   7080
agctggctct gccaagcaaa tatgtgaatt ttttatattt agctagtcat tatgaaaagt   7140
tgaagggtag tccagaagat aacgaacaaa aacaattgtt tgtggagcag cataagcatt   7200
atttagatga gattattgag caaatcagtg aattttctaa gcgtgttatt ttagcagatg   7260
ccaatttaga taaagttctt agtgcatata acaaacatag agacaaacca atacgtgaac   7320
aagcagaaaa tattattcat ttatttacgt tgacgaatct tggagctccc gctgctttta   7380
aatattttga tacaacaatt gatcgtaaac gatatacgtc tacaaaagaa gttttagatg   7440
ccactcttat ccatcaatcc atcactggtc tttatgaaac acgcattgat ttgagtcagc   7500
taggaggtga cggtggagga ggttctggag gtggaggttc tgctgagtat gtgcgagccc   7560
tctttgactt taatgggaat gatgaagagg atcttccctt taagaaagga gacatcctga   7620
gaatccggga taagcctgag gagcagtggt ggaatgcaga ggacagcgaa ggaaagaggg   7680
ggatgattcc tgtcccttac gtggagaagt attccggaga ctataaggac cacgacggag   7740
actacaagga tcatgatatt gattacaaag acgatgacga taagtctagg ctcgagtccg   7800
gagactataa ggaccacgac ggagactaca aggatcatga tattgattac aaagacgatg   7860
acgataagtc taggatgacc gacgctgagt acgtgagaat ccatgagaag ttggacatct   7920
```

-continued

```
acacgtttaa gaaacagttt ttcaacaaca aaaaatccgt gtcgcataga tgctacgttc   7980
tctttgaatt aaaacgacgg ggtgaacgta gagcgtgttt ttggggctat gctgtgaata   8040
aaccacagag cgggacagaa cgtggcattc acgccgaaat ctttagcatt agaaaagtcg   8100
aagaatacct gcgcgacaac cccggacaat tcacgataaa ttggtactca tcctggagtc   8160
cttgtgcaga ttgcgctgaa aagatcttag aatggtataa ccaggagctg cgggggaacg   8220
gccacacttt gaaaatctgg gcttgcaaac tctattacga gaaaaatgcg aggaatcaaa   8280
ttgggctgtg gaacctcaga gataacgggg ttgggttgaa tgtaatggta agtgaacact   8340
accaatgttg caggaaaata ttcatccaat cgtcgcacaa tcaattgaat gagaatagat   8400
ggcttgagaa gactttgaag cgagctgaaa aacgacggag cgagttgtcc attatgattc   8460
aggtaaaaat actccacacc actaagagtc ctgctgttac ttgacaggca tcaaataaaa   8520
cgaaaggctc agtcgaaaga ctgggccttt cgttttatct gttgtttgcg gccgggtacc   8580
gagctcgaat tcactggccg tcgttttaca acgtcgtgac tgggaaaacc ctggcgttac   8640
ccaacttaat cgccttgcag cacatccccc tttcgccagc tggcgtaata gcgaagaggc   8700
ccgcaccgat cgcccttccc aacagttgcg cagcctgaat ggcgaatggc gattcacaaa   8760
aaataggtac acgaaaaaca agttaaggga tgcagtttat gcatccctta acttacttat   8820
taaataattt atagctattg aaaagagata agaattgttc aaagctaata ttgtttaaat   8880
cgtcaattcc tgcatgtttt aaggaattgt taaattgatt ttttgtaaat attttcttgt   8940
attctttgtt aacccatttc ataacgaaat aattatactt ctgtttatct ttgtgtgata   9000
ttcttgattt ttttctattt aatctgataa gtgagctatt cactttaggt ttaggatgaa   9060
aatattctct tggaaccata cttaatatag aaatatcaac ttctgccatt aaaaataatg   9120
ccaatgagcg ttttgtattt aataatcttt tagcaaaccc gtattccacg attaaataaa   9180
tctcatcagc tatactatca aaaacaattt tgcgtattat atccgtactt atgttataag   9240
gtatattacc aaatatttta taggattggt ttttaggaaa tttaaactgc aatatatcct   9300
tgtttaaaac ttggaaatta tcgtgatcaa caagtttatt ttctgtagtt ttgcataatt   9360
tatggtctat ttcaatggca gttacgaaat tacacctctg tactaattca agggtaaaat   9420
gccctttcc tgagccgatt tcaaagatat tatcatgttc atttaatctt atatttgtca   9480
ttattttatc tatattatgt tttgaagtaa taaagttttg actgtgtttt atatttttct   9540
cgttcattat aaccctcttt attttttcct ccttataaaa ttagtataat tatagcacga   9600
gctctgataa atatgaacat gatgagtgat cgttaaattt atactgcaat ctgatgcgat   9660
tattgaataa aagatatgag agatttatct agtttctttt tttacaagaa aaaagaaagt   9720
tcttaaaggt tttatacttt tggtcgtaga gcacacggtt taacgactta attacgaagt   9780
aaataagtct agtgtgttag actttaatgt ttttttaagg cattagtgca tttaagcgtc   9840
agagcatggc tttatgccga gaaaactatt ggttggaatg gcgtgtgtgt tagccaaagc   9900
tttggcgagt tggttggggg tttcatggga ttaatcccat gaaagtacca actcaacaac   9960
acactaacgc ctgttggttc caaccaatag gaaattggaa taagcaatta gtataatgag  10020
agtataatgt tggtataacg ttagtataat gatgcttttt ttcattatat tttttatgta  10080
ctttaaacct gcacgcttat gtgaattaga aaaagcttaa tcgcatttca tagattgacc  10140
tcccaataac tacgtggtgt tattgggagg tcaatctatt tcatttgcct cttgctcaaa  10200
```

-continued

gttcccaaat tcgagtaaga ggtatttttg tttttggtcg tcgcctctca ttagtagttc 10260

agggtttaac attaatactc cagtttttct ttttataata tttccttctt ctaagatttt 10320

aagtgttgtt attactgttt gtagacttgt tcctgtagct tttgctattt ctcttgttgt 10380

agctatcatt gtattgttac ttaagtggac attatctagg atatagttaa cgattttaag 10440

ttttttttccg ccaatcatat ctaacatact tattaattgc actatatatg cctttacgaa 10500

gttaccagac gtttgtttac ggtataactt gtctacctct atgacttctc cactttcttc 10560

gtctatgagc ctctgagagc ctttatagac tgttccatat ctttctttca tctttttctc 10620

actccttatt ttaaactatt ctaactatat cataactgtt ctaaaaaaaa aagaacattt 10680

gttaaaagaa attagaacaa aatgagtgaa aaattagaac aaacaaattc cttataaacc 10740

ttatcatctc aacctatatt aagattttac ctagttgaat cttcttttct atataaagcg 10800

tcggagcata tcagggggtt atctaacgta aatgctaccc ttcggctcgc tttcgctcgg 10860

cattgac 10867

<210> SEQ ID NO 43
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: CAN1 ORF

<400> SEQUENCE: 43

ggggttaccg gcccagttgg attccgttat tggagaaacc caggtgcctg gggtccaggt 60

ataata 66

<210> SEQ ID NO 44
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: CAN1 ORF

<400> SEQUENCE: 44

ccccaatggc cgggtcaacc taaggcaata acctctttgg gtccacggac cccaggtcca 60

tattat 66

<210> SEQ ID NO 45
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: mutant sequence

<400> SEQUENCE: 45

ggggttaccg gcccagttgg attcccttat tggagaaacc caggtgcctg gggtccaggt 60

ataata 66

<210> SEQ ID NO 46
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target sequence

<400> SEQUENCE: 46

-continued

aaatggcgag gatacgttct ctatggagga tggcataggt 40

<210> SEQ ID NO 47
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target sequence

<400> SEQUENCE: 47

tttaccgctc ctatgcaaga gatacctcct accgtatcca 40

<210> SEQ ID NO 48
<211> LENGTH: 47
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: CAN1 ORF

<400> SEQUENCE: 48

gattccgtta ttggagaaac ccaggtgcct ggggtccagg tataata 47

<210> SEQ ID NO 49
<211> LENGTH: 47
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: CAN1 ORF

<400> SEQUENCE: 49

ctaaggcaat aacctctttg ggtccacgga ccccaggtcc atattat 47

<210> SEQ ID NO 50
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Ade1

<400> SEQUENCE: 50

taacgataat gtcaattacg aagactgaac tggacggtat 40

<210> SEQ ID NO 51
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Ade1

<400> SEQUENCE: 51

Met Ser Ile Thr Lys Thr Glu Leu Asp Gly Ile
1 5 10

<210> SEQ ID NO 52
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Ade1

<400> SEQUENCE: 52

taacgataat gtgaattacg aagactgaac tggacggtat 40

-continued

<210> SEQ ID NO 53
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Ade1

<400> SEQUENCE: 53

taacgataat gttaattacg aagactgaac tggacggtat 40

<210> SEQ ID NO 54
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Can1

<400> SEQUENCE: 54

ggggttaccg gcccagttgg attccgttat tggagaaacc 40

<210> SEQ ID NO 55
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Can1

<400> SEQUENCE: 55

Gly Val Thr Gly Pro Val Gly Phe Arg Tyr Trp Arg Asn
1 5 10

<210> SEQ ID NO 56
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Can1

<400> SEQUENCE: 56

ggggttaccg gcccagttgg attcccttat tggagaaacc 40

<210> SEQ ID NO 57
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Can1

<400> SEQUENCE: 57

ggggttaccg gcccagttgg attccattat tggagaaacc 40

<210> SEQ ID NO 58
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Can1

<400> SEQUENCE: 58

ggggttaccg gcccagttga attcccttat tggagaaacc 40

<210> SEQ ID NO 59
<211> LENGTH: 40
<212> TYPE: DNA

-continued

<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Can1

<400> SEQUENCE: 59

ggggttaccg gcccagttgg attcctttat tggagaaacc 40

<210> SEQ ID NO 60
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: WT-Ade1

<400> SEQUENCE: 60

acgataatgt caattacgaa g 21

<210> SEQ ID NO 61
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: galK

<400> SEQUENCE: 61

tcaatgggct aactacgttc 20

<210> SEQ ID NO 62
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: galK

<400> SEQUENCE: 62

ttaatgggct aactacgttc 20

<210> SEQ ID NO 63
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: rpoB

<400> SEQUENCE: 63

gctgtctcag tttatggacc 20

<210> SEQ ID NO 64
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: rpoB

<400> SEQUENCE: 64

cgacagagtc aaatacctgg 20

<210> SEQ ID NO 65
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: rpoB

-continued

<400> SEQUENCE: 65

gctgtctcag tttatggacc 20

<210> SEQ ID NO 66
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: rpoB

<400> SEQUENCE: 66

gctgtctcag tttatgaacc 20

<210> SEQ ID NO 67
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: rpoB

<400> SEQUENCE: 67

gctgtctcag tttataaacc 20

<210> SEQ ID NO 68
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: rpoB

<400> SEQUENCE: 68

cgacagagtc aaatacttgg 20

<210> SEQ ID NO 69
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 69

tcgcttgaac atccagcgaa acaggccccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 70
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 70

tcgcttgaac atccagcgaa acaggttccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 71
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 71

tcgcttgaac atccagcgaa acaggtcccc cccatcgagc agaaaacggt ggtggatggc 60

-continued

<210> SEQ ID NO 72
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 72

tcgcttgaac atccagcgaa acaggccccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 73
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 73

tcgcttgaac atccagcgaa acaggccccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 74
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 74

tcgcttgaac atccagcgaa acaggccccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 75
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 75

tcgcttgaac atccagcgaa acaggtcccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 76
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 76

tcgcttgaac atccagcgaa acaggccccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 77
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 77

tcgcttgaac atccagcgaa acaggccccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 78
<211> LENGTH: 60
<212> TYPE: DNA

-continued

<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 78

tcgcttgaac atccagcgaa acaggcctcc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 79
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 79

tcgcttgaac atccagcgaa acaggccttc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 80
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 80

tcgcttgaac atccagcgaa acaggccttc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 81
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 81

tcgcttgaac atccagcgaa acaggccttc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 82
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 82

tcgcttgaac atccagcgaa acaggccttc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 83
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 83

tcgcttgaac atccagcgaa acaggccccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 84
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

-continued

<400> SEQUENCE: 84

tcgcttgaac atccagcgaa acaggccttt cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 85
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 85

tcgcttgaac atccagcgaa acaggccctt cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 86
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 86

tcgcttgaac atccagcgaa acaggcccct cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 87
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 87

tcgcttgaac atccagcgaa acaggcccca cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 88
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 88

tcgcttgaac atccagcgaa acaggcccct tccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 89
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: target

<400> SEQUENCE: 89

tcgcttgaac atccagcgaa acaggccccc cccatcgagc agaaaacggt ggtggatggc 60

<210> SEQ ID NO 90
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: rpoB1r

<400> SEQUENCE: 90

gctgtctcag tttatggacc 20

-continued

```
<210> SEQ ID NO 91
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: rpoB1r

<400> SEQUENCE: 91

gctgtctcag tttatgaacc                                                   20


<210> SEQ ID NO 92
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: galK 8

<400> SEQUENCE: 92

actcacacca ttcaggcgcc                                                   20


<210> SEQ ID NO 93
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: galK 8

<400> SEQUENCE: 93

acttacacca ttcaggcgcc                                                   20


<210> SEQ ID NO 94
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: galK 12

<400> SEQUENCE: 94

tcaatgggct aactacgttc g                                                 21


<210> SEQ ID NO 95
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: galK 12

<400> SEQUENCE: 95

ttaatgggct aactacgttc g                                                 21
```

What is claimed is:

1. A method of modifying a targeted site of a double stranded DNA, comprising:

contacting said double stranded DNA with at least one complex which comprises (i) a nucleic acid base converting enzyme linked to (ii) a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in the targeted site of the double stranded DNA,

thereby to convert one or more nucleotides in the targeted site to one or more different nucleotides or to delete one or more nucleotides in the targeted site or to insert one or more nucleotides into said targeted site, without introducing a double strand break (DSB) in said double stranded DNA in the targeted site,

wherein the nucleic acid sequence-recognizing module is a CRISPR-Cas system, and wherein the CRISPR-Cas system comprises a nickase protein.

2. The method of claim **1** which comprises contacting the double stranded DNA with two or more complexes that each comprise a nucleic sequence-recognizing module that specifically binds to a different target nucleotide sequence.

3. The method of claim **2**, wherein the different target nucleotide sequences are present in different genes.

4. The method of claim **1**, wherein the nucleic acid base converting enzyme is a deaminase.

5. The method of claim **4**, wherein the deaminase is a cytidine deaminase.

6. The method of claim **1**, wherein the step of contacting comprises introducing a nucleic acid encoding the at least one complex into a cell which comprises the double stranded DNA.

7. The method of claim **6**, wherein the cell is a prokaryotic cell, an eukaryotic cell, a microbial cell, a plant cell, an insect cell, an animal cell, a vertebrate cell, or a mammalian cell.

8. A method of modifying a targeted site in double stranded genomic DNA in each of two or more targeted alleles on homologous chromosomes in a polyploid cell, the method comprising:

contacting said double stranded genomic DNA of the polyploid cell with at least one complex which comprises (i) a nucleic acid base converting enzyme linked to (ii) a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in the targeted site in the double stranded genomic DNA in each of said two or more targeted alleles on homologous chromosomes in the polyploid cell,

thereby to convert one or more nucleotides in said targeted site in the double stranded genomic DNA in each of said two or more targeted alleles on homologous chromosomes to one or more different nucleotides, or to delete one or more nucleotides in said targeted site in the double stranded genomic DNA in each of said two or more targeted alleles on homologous chromosomes, or to insert one or more nucleotides into said targeted site in the double stranded genomic DNA in each of said two or more targeted alleles on homologous chromosomes,

without introducing a double strand break (DSB) in said double stranded genomic DNA, wherein the nucleic acid sequence-recognizing module is a CRISPR-Cas system, and wherein the CRISPR-Cas system comprises a nickase protein.

9. The method of claim **6**, wherein the step of introducing the nucleic acid encoding the at least one complex into the cell comprises introducing an expression vector comprising the nucleic acid encoding the at least one complex into the cell, wherein the nucleic acid is under regulation of an inducible regulatory region, the method further comprising a step of inducing expression of the nudeic acid for an expression period to stabilize the conversion of one or more nucleotides in the targeted site to one or more different nucleotides, or the deletion of one or more nucleotides, or the insertion of one or more nucleotides into said targeted site in the double stranded DNA

10. The method of claim **9**, wherein the target nucleotide sequence in the targeted site in the double stranded DNA is present in a gene essential for survival of the cell.

11. A nudeic acid-modifying enzyme complex, comprising:

a nucleic acid base converting enzyme, linked to

(ii) a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a targeted site of a double stranded DNA,

wherein the nucleic acid sequence-recognizing module is a CRISPR-Cas system comprising either a Cas protein that is incapable of introducing a double strand break (DSB) in double stranded DNA or a Cas protein in which cleavage activity for only one strand of double stranded DNA has been inactivated,

and wherein the complex is capable of converting one or more nucleotides in the targeted site to one or more other nudeotides, or is capable of deleting one or more nucleotides, or is capable of inserting one or more nucleotides into said targeted site, without introducing a double strand break (DSB) in double stranded DNA in the targeted site.

12. A nucleic add encoding the nucleic acid-modifying enzyme complex of claim **11**.

13. The method of claim **1**, wherein the nickase protein is a Cas9 D10A mutant nickase protein (nCas9(D10A)).

14. The method of claim **1**, wherein the nickase protein is a Cas9 H840A mutant nickase protein (nCas9(H840A)).

15. The nucleic acid-modifying enzyme complex of claim **11**, wherein only one of two DNA cleavage abilities of the Cas protein is inactivated.

16. A nucleic acid encoding the nucleic acid-modifying enzyme complex of claim **15**.

* * * * *